Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,800 | 2021-11-15 00:00:00 UTC | 2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against a Market Crash | ABBV | https://www.nasdaq.com/articles/2-high-yield-dividend-stocks-that-can-safeguard-your-portfolio-against-a-market-crash-2021 | null | null | Stock market corrections are part and parcel of the investing process. As such, investors shouldn't get too worked about this inevitability. The current market, though, is starting to show ominous warning signs about a potential downturn. Valuations across the large cap space appear to be stretched in many instances, w... | Keeping with this theme, the healthcare giants AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) both sport handsome dividend yields, well-rounded product portfolios, and valuations that are downright bargains relative to their large-cap peers. AbbVie: A Dividend Aristocrat trading at a deep discount Illinois-base... | Keeping with this theme, the healthcare giants AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) both sport handsome dividend yields, well-rounded product portfolios, and valuations that are downright bargains relative to their large-cap peers. AbbVie: A Dividend Aristocrat trading at a deep discount Illinois-base... | Keeping with this theme, the healthcare giants AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) both sport handsome dividend yields, well-rounded product portfolios, and valuations that are downright bargains relative to their large-cap peers. AbbVie: A Dividend Aristocrat trading at a deep discount Illinois-base... | Keeping with this theme, the healthcare giants AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) both sport handsome dividend yields, well-rounded product portfolios, and valuations that are downright bargains relative to their large-cap peers. AbbVie: A Dividend Aristocrat trading at a deep discount Illinois-base... |
23,801 | 2021-11-15 00:00:00 UTC | 5 Long-Term Investments You'll Thank Yourself for Later | ABBV | https://www.nasdaq.com/articles/5-long-term-investments-youll-thank-yourself-for-later-2021-11-15 | null | null | Many of us are so busy with our day-to-day lives, making short-term decisions left and right, that we don't pay much attention to the long term -- to our futures. When we do think about it, we often put off doing things that we ought to do -- like saving and investing for our retirement years. That can be a costly erro... | 5.3% Verizon Communications 4.9% AbbVie 4.8% Chevron 4.7% Duke Energy 3.9% Walgreens Boots Alliance 3.8% Kellogg 3.7% Selena Maranjian owns shares of AbbVie. Many of us are so busy with our day-to-day lives, making short-term decisions left and right, that we don't pay much attention to the long term -- to our futures. | 5.3% Verizon Communications 4.9% AbbVie 4.8% Chevron 4.7% Duke Energy 3.9% Walgreens Boots Alliance 3.8% Kellogg 3.7% Selena Maranjian owns shares of AbbVie. Some index funds worth considering are the SPDR S&P 500 ETF, Vanguard Total Stock Market ETF, and Vanguard Total World Stock ETF, which will, respectively, spread... | 5.3% Verizon Communications 4.9% AbbVie 4.8% Chevron 4.7% Duke Energy 3.9% Walgreens Boots Alliance 3.8% Kellogg 3.7% Selena Maranjian owns shares of AbbVie. Some index funds worth considering are the SPDR S&P 500 ETF, Vanguard Total Stock Market ETF, and Vanguard Total World Stock ETF, which will, respectively, spread... | 5.3% Verizon Communications 4.9% AbbVie 4.8% Chevron 4.7% Duke Energy 3.9% Walgreens Boots Alliance 3.8% Kellogg 3.7% Selena Maranjian owns shares of AbbVie. Well, consider our investing philosophy at The Motley Fool, which is to buy 25 or more stocks, expecting to hold them for at least five years. |
23,802 | 2021-11-14 00:00:00 UTC | 4 Fantastic Dividend Stocks to Buy With Yields of 4% or More | ABBV | https://www.nasdaq.com/articles/4-fantastic-dividend-stocks-to-buy-with-yields-of-4-or-more-2021-11-14 | null | null | Trade-offs can often be a necessary evil in investing. For example, you might have to take on more risk than you'd like to obtain a higher dividend payout.
However, you don't always have to make big trade-offs. Some companies have solid businesses and pay juicy dividends. Here are four fantastic dividend stocks to buy ... | AbbVie's acquisition of Allergan and newer products including psoriasis drug Skyrizi should help the company move past its Humira headwinds and keep the dividends coming. AbbVie Income-seeking investors tend to especially like Dividend Aristocrats. AbbVie (NYSE: ABBV) recently extended its streak of dividend hikes to 5... | AbbVie Income-seeking investors tend to especially like Dividend Aristocrats. AbbVie (NYSE: ABBV) recently extended its streak of dividend hikes to 50 years. AbbVie's product lineup includes 11 blockbuster drugs. | See the 10 stocks *Stock Advisor returns as of November 10, 2021 Keith Speights owns shares of AbbVie, Devon Energy, and Enterprise Products Partners. AbbVie Income-seeking investors tend to especially like Dividend Aristocrats. AbbVie (NYSE: ABBV) recently extended its streak of dividend hikes to 50 years. | AbbVie Income-seeking investors tend to especially like Dividend Aristocrats. AbbVie (NYSE: ABBV) recently extended its streak of dividend hikes to 50 years. AbbVie's product lineup includes 11 blockbuster drugs. |
23,803 | 2021-11-13 00:00:00 UTC | Believe It or Not, These Stocks Pay You to Own Them | ABBV | https://www.nasdaq.com/articles/believe-it-or-not-these-stocks-pay-you-to-own-them-2021-11-13 | null | null | Most (or all) of us would love extra income, but few of us are eager to take on a second job in order to get it. Fortunately, there are other ways to get extra income -- including passive income.
Passive income is hard to beat because it requires little effort from you. Once you buy an annuity, for example, you can sit... | AbbVie 4.8% 18% Automatic Data Processing 1.6% 12% Cisco Systems 2.6% 7% Clorox 2.8% 8% Coca-Cola 3% 4% Corning 2.5% 12% Lowe's 1.4% 14% PepsiCo 2.6% 7% Starbucks 1.7% 18% Verizon Communications 4.9% 2% Walgreens Boots Alliance 3.8% 5% Waste Management 1.4% 7% Data source: Yahoo! See the 10 stocks *Stock Advisor return... | AbbVie 4.8% 18% Automatic Data Processing 1.6% 12% Cisco Systems 2.6% 7% Clorox 2.8% 8% Coca-Cola 3% 4% Corning 2.5% 12% Lowe's 1.4% 14% PepsiCo 2.6% 7% Starbucks 1.7% 18% Verizon Communications 4.9% 2% Walgreens Boots Alliance 3.8% 5% Waste Management 1.4% 7% Data source: Yahoo! See the 10 stocks *Stock Advisor return... | AbbVie 4.8% 18% Automatic Data Processing 1.6% 12% Cisco Systems 2.6% 7% Clorox 2.8% 8% Coca-Cola 3% 4% Corning 2.5% 12% Lowe's 1.4% 14% PepsiCo 2.6% 7% Starbucks 1.7% 18% Verizon Communications 4.9% 2% Walgreens Boots Alliance 3.8% 5% Waste Management 1.4% 7% Data source: Yahoo! See the 10 stocks *Stock Advisor return... | AbbVie 4.8% 18% Automatic Data Processing 1.6% 12% Cisco Systems 2.6% 7% Clorox 2.8% 8% Coca-Cola 3% 4% Corning 2.5% 12% Lowe's 1.4% 14% PepsiCo 2.6% 7% Starbucks 1.7% 18% Verizon Communications 4.9% 2% Walgreens Boots Alliance 3.8% 5% Waste Management 1.4% 7% Data source: Yahoo! See the 10 stocks *Stock Advisor return... |
23,804 | 2021-11-11 00:00:00 UTC | LABU, ALXO, ABBV, ACAD: Large Outflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/labu-alxo-abbv-acad%3A-large-outflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $95.7 million dollar outflow -- that's a 12.8% decrease week over week (from 13,711,600 to 11,961,600). ... | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ... | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. For a complete list of holdings, visit the LABU Holdings page » The chart below s... | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ... | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ... |
23,805 | 2021-11-10 00:00:00 UTC | First Week of December 17th Options Trading For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/first-week-of-december-17th-options-trading-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 17th contracts and identified one put and one call contract of particular interest.
The... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $115.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $120.00 strike price has a current bid of $1.68. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 17th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $120.00 strike highlighted in red: Consi... |
23,806 | 2021-11-09 00:00:00 UTC | First Week of May 2022 Options Trading For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/first-week-of-may-2022-options-trading-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading this week, for the May 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 192 days until expiration the newly trading contracts represent a potential opportunity for selle... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing ABBV's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considering the fact that the $120.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new May 2022 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $120.00 strike highlighted in red: Considerin... |
23,807 | 2021-11-08 00:00:00 UTC | Notable Monday Option Activity: JPM, NCLH, ABBV | ABBV | https://www.nasdaq.com/articles/notable-monday-option-activity%3A-jpm-nclh-abbv | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in JPMorgan Chase & Co (Symbol: JPM), where a total volume of 45,894 contracts has been traded thus far today, a contract volume which is representative of approximately 4.6 million underlying shares (given tha... | Particularly high volume was seen for the $120 strike call option expiring February 18, 2022, with 4,789 contracts trading so far today, representing approximately 478,900 underlying shares of ABBV. Below is a chart showing NCLH's trailing twelve month trading history, with the $28 strike highlighted in orange: And Abb... | Below is a chart showing NCLH's trailing twelve month trading history, with the $28 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,585 contracts, representing approximately 2.6 million underlying shares or approximately 40.5% of ABBV's average daily trading volume over the ... | Below is a chart showing NCLH's trailing twelve month trading history, with the $28 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,585 contracts, representing approximately 2.6 million underlying shares or approximately 40.5% of ABBV's average daily trading volume over the ... | Below is a chart showing NCLH's trailing twelve month trading history, with the $28 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,585 contracts, representing approximately 2.6 million underlying shares or approximately 40.5% of ABBV's average daily trading volume over the ... |
23,808 | 2021-11-08 00:00:00 UTC | 3 Best Biotech Stocks to Buy in November | ABBV | https://www.nasdaq.com/articles/3-best-biotech-stocks-to-buy-in-november | null | null | For income investors, building a diversified portfolio of dividend stocks should be a top priority. That's because owning a wide array of stocks that span numerous industries reduces your risk profile. A payout cut for a stock that produces 1% of your total dividend income is far less painful than a cut for a stock tha... | AbbVie AbbVie (NYSE: ABBV) manufactures the top-selling prescription drug in the world: Humira, an immunosuppressive used to treat a number of conditions. And while that may lead investors to worry that AbbVie is a yield trap, shareholders should actually be able to sleep well at night. Based on AbbVie's drug portfolio... | Humira will lose patent protection in the U.S. in 2023, but AbbVie's next-generation drugs Skyrizi and Rinvoq have contributed 71% of AbbVie's immunology segment revenue growth year to date. See the 10 stocks *Stock Advisor returns as of October 20, 2021 Kody Kester owns shares of AbbVie, Bristol Myers Squibb, and Merc... | Humira will lose patent protection in the U.S. in 2023, but AbbVie's next-generation drugs Skyrizi and Rinvoq have contributed 71% of AbbVie's immunology segment revenue growth year to date. AbbVie's dividend payout ratio will be in the low-40% range for this year, which should leave it plenty of cushion to absorb a te... | Humira will lose patent protection in the U.S. in 2023, but AbbVie's next-generation drugs Skyrizi and Rinvoq have contributed 71% of AbbVie's immunology segment revenue growth year to date. See the 10 stocks *Stock Advisor returns as of October 20, 2021 Kody Kester owns shares of AbbVie, Bristol Myers Squibb, and Merc... |
23,809 | 2021-11-08 00:00:00 UTC | AbbVie Presents Data from Two Phase 3 Trials on Risankizumab | ABBV | https://www.nasdaq.com/articles/abbvie-presents-data-from-two-phase-3-trials-on-risankizumab | null | null | AbbVie (ABBV) has presented integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2. These studies are designed to evaluate the efficacy and safety of risankizumab (SKYRIZI) in adult patients with active psoriatic arthritis (PsA).
The data demonstrated by the biopharmaceutical company showed that 2... | Pipeline execution has been strong with recent Qulipta/Vuity approvals, and positive Ph3 data for ABBV-951 and Vraylar MDD, which should help drive multiple expansion." AbbVie (ABBV) has presented integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2. The CSO of AbbVie, Thomas Hudson, said, "Psori... | The average AbbVie price target of $130.56 implies 11.42% upside potential from current levels. AbbVie (ABBV) has presented integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2. The CSO of AbbVie, Thomas Hudson, said, "Psoriatic arthritis is a chronic, progressive and debilitating disease. | (See AbbVie stock charts on TipRanks) Wall Street’s Take Recently, BMO Capital analyst Gary Nachman reiterated a Buy rating on the stock and lifted the price target to $134 (14.35% upside potential) from $133. AbbVie (ABBV) has presented integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2. The C... | (See AbbVie stock charts on TipRanks) Wall Street’s Take Recently, BMO Capital analyst Gary Nachman reiterated a Buy rating on the stock and lifted the price target to $134 (14.35% upside potential) from $133. AbbVie (ABBV) has presented integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2. The C... |
23,810 | 2021-11-07 00:00:00 UTC | Trade Alert: The Independent Director Of AbbVie Inc. (NYSE:ABBV), Roxanne Austin, Has Sold Some Shares Recently | ABBV | https://www.nasdaq.com/articles/trade-alert%3A-the-independent-director-of-abbvie-inc.-nyse%3Aabbv-roxanne-austin-has-sold | null | null | Some AbbVie Inc. (NYSE:ABBV) shareholders may be a little concerned to see that the Independent Director, Roxanne Austin, recently sold a substantial US$8.4m worth of stock at a price of US$117 per share. That diminished their holding by a very significant 86%, which arguably implies a strong desire to reallocate capit... | Some AbbVie Inc. (NYSE:ABBV) shareholders may be a little concerned to see that the Independent Director, Roxanne Austin, recently sold a substantial US$8.4m worth of stock at a price of US$117 per share. The Last 12 Months Of Insider Transactions At AbbVie In fact, the recent sale by Roxanne Austin was the biggest sal... | Some AbbVie Inc. (NYSE:ABBV) shareholders may be a little concerned to see that the Independent Director, Roxanne Austin, recently sold a substantial US$8.4m worth of stock at a price of US$117 per share. The Last 12 Months Of Insider Transactions At AbbVie In fact, the recent sale by Roxanne Austin was the biggest sal... | The Last 12 Months Of Insider Transactions At AbbVie In fact, the recent sale by Roxanne Austin was the biggest sale of AbbVie shares made by an insider individual in the last twelve months, according to our records. NYSE:ABBV Insider Trading Volume November 7th 2021 For those who like to find winning investments this ... | Some AbbVie Inc. (NYSE:ABBV) shareholders may be a little concerned to see that the Independent Director, Roxanne Austin, recently sold a substantial US$8.4m worth of stock at a price of US$117 per share. So What Do The AbbVie Insider Transactions Indicate? An insider hasn't bought AbbVie stock in the last three months... |
23,811 | 2021-11-07 00:00:00 UTC | Investing $100,000 in These Dividend Stocks Could Give You Nearly $6,000 in Steady Annual Income | ABBV | https://www.nasdaq.com/articles/investing-%24100000-in-these-dividend-stocks-could-give-you-nearly-%246000-in-steady-annual | null | null | With apologies to the rock band Dire Straits, you're not going to get "money for nothing." However, you can definitely get money on a regular basis by buying the right stocks. I'm referring, of course, to buying solid dividend stocks.
Many dividend stocks don't have high enough yields to generate significant income. Ot... | AbbVie If you take one-third of your initial $100,000 and buy shares of AbbVie (NYSE: ABBV), you should be able to count on at least $1,600 in annual income. AbbVie ranks as a Dividend Aristocrat, members of the S&P 500 that have raised their dividends for at least 25 consecutive years. With the company's recently anno... | With the company's recently announced dividend hike, AbbVie's streak will extend to 50 years in a row of dividend increases. AbbVie If you take one-third of your initial $100,000 and buy shares of AbbVie (NYSE: ABBV), you should be able to count on at least $1,600 in annual income. AbbVie ranks as a Dividend Aristocrat... | With the company's recently announced dividend hike, AbbVie's streak will extend to 50 years in a row of dividend increases. Enterprise Products Partners AbbVie and Easterly together should be able to give you $3,320 in annual income from dividends. AbbVie If you take one-third of your initial $100,000 and buy shares o... | Enterprise Products Partners AbbVie and Easterly together should be able to give you $3,320 in annual income from dividends. AbbVie If you take one-third of your initial $100,000 and buy shares of AbbVie (NYSE: ABBV), you should be able to count on at least $1,600 in annual income. AbbVie ranks as a Dividend Aristocrat... |
23,812 | 2021-11-05 00:00:00 UTC | AbbVie Says Phase 3 Data On Risankizumab Shows Greater Improvements In Psoriatic Arthritis Signs | ABBV | https://www.nasdaq.com/articles/abbvie-says-phase-3-data-on-risankizumab-shows-greater-improvements-in-psoriatic-arthritis | null | null | (RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in adult patients with active psoriatic arthritis.
These results will be featured in an American College of Rheumatology Con... | (RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in adult patients with active psoriatic arthritis. Risankizumab is part of a collaboration between Boehringer Ingelheim and ... | (RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in adult patients with active psoriatic arthritis. Risankizumab is part of a collaboration between Boehringer Ingelheim and ... | (RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in adult patients with active psoriatic arthritis. Risankizumab is part of a collaboration between Boehringer Ingelheim and ... | (RTTNews) - AbbVie (ABBV) said that it will present integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, which evaluated the efficacy and safety of risankizumab or SKYRIZI in adult patients with active psoriatic arthritis. Risankizumab is part of a collaboration between Boehringer Ingelheim and ... |
23,813 | 2021-11-05 00:00:00 UTC | What's Next For Merck Stock After An Upbeat Q3? | ABBV | https://www.nasdaq.com/articles/whats-next-for-merck-stock-after-an-upbeat-q3-2021-11-05 | null | null | [Updated: Nov 3, 2021] MRK Stock Update
Merck (NYSE: MRK) recently reported its Q3 results, which were better than our estimates. The company reported sales of around $13.2 billion (up 20% y-o-y), compared to our estimate of $12.2 billion. While the Keytruda sales saw a 22% rise to $4.5 billion, Gardasil sales surged 6... | Given these changes to our revenues and earnings forecast, we have revised our Merck’s Valuation to $98 per share, based on $6.02 expected adjusted EPS and maintaining a 16x P/E multiple for 2021, implying an 11% upside from its current levels of $88. While we expect the revenue and earnings to fall below the consensus... | [Updated: Nov 3, 2021] MRK Stock Update Merck (NYSE: MRK) recently reported its Q3 results, which were better than our estimates. We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-19 delta variant likely impacted the company’s overall vaccine sales growth, i... | Following a solid performance in Q3, Merck raised its full year outlook for sales to be in the range of $47.4 billion and $47.9 billion, compared to its earlier estimate of $46.4 billion to $47.4 billion. Merck now expects Molnupiravir sales to be around $7 billion through 2022, including $0.5 billion to $1.0 billion s... | The company reported sales of around $13.2 billion (up 20% y-o-y), compared to our estimate of $12.2 billion. We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-19 delta variant likely impacted the company’s overall vaccine sales growth, including that for Ga... |
23,814 | 2021-11-03 00:00:00 UTC | Best Stocks To Buy Today? 4 Dividend Stocks To Check Out | ABBV | https://www.nasdaq.com/articles/best-stocks-to-buy-today-4-dividend-stocks-to-check-out-2021-11-03 | null | null | 4 Top Dividend Stocks In Focus For November 2021
With a booming stock market and the Federal Reserve potentially easing its economic aid, we could arguably see some volatility. Accordingly, in times of uncertainty in the market, dividend stocks would be in focus. Sure, there would be some wondering what are meme stocks... | Best Dividend Stocks To Buy [Or Sell] This Week Walmart Inc. (NYSE: WMT) Home Depot Inc. (NYSE: HD) Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) Walmart Inc. First up, we have Walmart, a multinational retail corporation with its chain of grocery stores, hypermarkets, and discount department stores. Source: TD Ameri... | Best Dividend Stocks To Buy [Or Sell] This Week Walmart Inc. (NYSE: WMT) Home Depot Inc. (NYSE: HD) Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) Walmart Inc. First up, we have Walmart, a multinational retail corporation with its chain of grocery stores, hypermarkets, and discount department stores. Source: TD Ameri... | Best Dividend Stocks To Buy [Or Sell] This Week Walmart Inc. (NYSE: WMT) Home Depot Inc. (NYSE: HD) Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) Walmart Inc. First up, we have Walmart, a multinational retail corporation with its chain of grocery stores, hypermarkets, and discount department stores. Source: TD Ameri... | Best Dividend Stocks To Buy [Or Sell] This Week Walmart Inc. (NYSE: WMT) Home Depot Inc. (NYSE: HD) Pfizer Inc. (NYSE: PFE) AbbVie Inc. (NYSE: ABBV) Walmart Inc. First up, we have Walmart, a multinational retail corporation with its chain of grocery stores, hypermarkets, and discount department stores. Source: TD Ameri... |
23,815 | 2021-11-03 00:00:00 UTC | 7 Dividend Aristocrat Stocks That Should Grace Your Portfolio | ABBV | https://www.nasdaq.com/articles/7-dividend-aristocrat-stocks-that-should-grace-your-portfolio-2021-11-03 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It’s pretty easy to continue to buy growth in this market. Third-quarter earnings for big tech companies are crushing it. The economy is climbing the wall of worry that supply chain issues are promising. So why buy dividend aristocrat stocks?
Well, first of... | AbbVie (NYSE:ABBV) General Dynamics (NYSE:GD) Lowe’s (NYSE:LOW) Nucor (NYSE:NUE) Target (NYSE:TGT) T Rowe Price (NASDAQ:TROW) Dividend Aristocrat Stocks: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com As we’ll soon see, not all dividend aristocrat s... | General Dynamics (NYSE:GD) Lowe’s (NYSE:LOW) Nucor (NYSE:NUE) Target (NYSE:TGT) T Rowe Price (NASDAQ:TROW) Dividend Aristocrat Stocks: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com As we’ll soon see, not all dividend aristocrat stocks seem to fit t... | General Dynamics (NYSE:GD) Lowe’s (NYSE:LOW) Nucor (NYSE:NUE) Target (NYSE:TGT) T Rowe Price (NASDAQ:TROW) Dividend Aristocrat Stocks: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com As we’ll soon see, not all dividend aristocrat stocks seem to fit t... | General Dynamics (NYSE:GD) Lowe’s (NYSE:LOW) Nucor (NYSE:NUE) Target (NYSE:TGT) T Rowe Price (NASDAQ:TROW) Dividend Aristocrat Stocks: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com As we’ll soon see, not all dividend aristocrat stocks seem to fit t... |
23,816 | 2021-11-03 00:00:00 UTC | 3 Explosive Biotech Stocks -- Could They Shoot Even Higher? | ABBV | https://www.nasdaq.com/articles/3-explosive-biotech-stocks-could-they-shoot-even-higher-2021-11-03 | null | null | Investors hungry for stocks that can make big moves in a short amount of time know the biotech industry is the best place to look. A new drug approval, or simply clinical trial results that suggest success can push small-cap stocks through the roof.
Recently, Cara Therapeutics (NASDAQ: CARA), Enanta Pharmaceuticals (NA... | Its lead revenue stream comes from AbbVie. Cara Therapeutics lead drug, Korsuva is an interesting new opioid that earned FDA approval earlier this year to reduce itching associated with hemodialysis treatment. Cara Therapeutics stock crashed in April when an oral version of Korsuva failed to significantly reduce itchin... | Its lead revenue stream comes from AbbVie. A new drug approval, or simply clinical trial results that suggest success can push small-cap stocks through the roof. Recently, Cara Therapeutics (NASDAQ: CARA), Enanta Pharmaceuticals (NASDAQ: ENTA), Ocugen (NASDAQ: OCGN) made big moves in the right direction. | Its lead revenue stream comes from AbbVie. Cara Therapeutics stock crashed in April when an oral version of Korsuva failed to significantly reduce itching for eczema patients in a phase 2 trial after 12 weeks of treatment. Investors have been driving Enanta Pharmaceuticals stock higher in anticipation of a new oral ant... | Its lead revenue stream comes from AbbVie. Recently, Cara Therapeutics (NASDAQ: CARA), Enanta Pharmaceuticals (NASDAQ: ENTA), Ocugen (NASDAQ: OCGN) made big moves in the right direction. Ocugen Shares of this biotech stock surged around 65% higher in October. |
23,817 | 2021-11-02 00:00:00 UTC | Why Teva Pharmaceutical Stock Is Jumping Today | ABBV | https://www.nasdaq.com/articles/why-teva-pharmaceutical-stock-is-jumping-today-2021-11-02 | null | null | What happened
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were jumping 7.1% as of 11:10 a.m. EDT on Tuesday. The solid gain came following a California court ruling yesterday in favor of Teva and three other drugmakers in opioid-related litigation filed by Orange, Los Angeles, and Santa Clara counties, and th... | So what The three California counties and Oakland had alleged that Teva, AbbVie (NYSE: ABBV), Endo International (NASDAQ: ENDP), and Johnson & Johnson (NYSE: JNJ) caused a public nuisance and made false or misleading statements related to marketing opioid drugs in California. Both companies have more at stake with opio... | So what The three California counties and Oakland had alleged that Teva, AbbVie (NYSE: ABBV), Endo International (NASDAQ: ENDP), and Johnson & Johnson (NYSE: JNJ) caused a public nuisance and made false or misleading statements related to marketing opioid drugs in California. Both companies have more at stake with opio... | So what The three California counties and Oakland had alleged that Teva, AbbVie (NYSE: ABBV), Endo International (NASDAQ: ENDP), and Johnson & Johnson (NYSE: JNJ) caused a public nuisance and made false or misleading statements related to marketing opioid drugs in California. Both companies have more at stake with opio... | So what The three California counties and Oakland had alleged that Teva, AbbVie (NYSE: ABBV), Endo International (NASDAQ: ENDP), and Johnson & Johnson (NYSE: JNJ) caused a public nuisance and made false or misleading statements related to marketing opioid drugs in California. Both companies have more at stake with opio... |
23,818 | 2021-11-02 00:00:00 UTC | Bristol Myers Squibb Just Got Some Great Regulatory News | ABBV | https://www.nasdaq.com/articles/bristol-myers-squibb-just-got-some-great-regulatory-news-2021-11-02 | null | null | It's no secret that Bristol Myers Squibb (NYSE: BMY) will need to innovate to grow as its three top drugs -- Revlimid, Eliquis, and Opdivo -- face patent expirations during the next decade. Fortunately, Bristol Myers Squibb got great news from a major European regulatory agency earlier this month.
The Committee for Med... | There are a number of drugs already on the market for moderate to severe ulcerative colitis, such as AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara. See the 10 stocks *Stock Advisor returns as of October 20, 2021 Kody Kester owns shares of AbbVie, Bristol Myers Squibb, and Johnson & Johnson. I... | See the 10 stocks *Stock Advisor returns as of October 20, 2021 Kody Kester owns shares of AbbVie, Bristol Myers Squibb, and Johnson & Johnson. There are a number of drugs already on the market for moderate to severe ulcerative colitis, such as AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara. T... | There are a number of drugs already on the market for moderate to severe ulcerative colitis, such as AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara. See the 10 stocks *Stock Advisor returns as of October 20, 2021 Kody Kester owns shares of AbbVie, Bristol Myers Squibb, and Johnson & Johnson. L... | There are a number of drugs already on the market for moderate to severe ulcerative colitis, such as AbbVie's (NYSE: ABBV) Humira and Johnson & Johnson's (NYSE: JNJ) Stelara. See the 10 stocks *Stock Advisor returns as of October 20, 2021 Kody Kester owns shares of AbbVie, Bristol Myers Squibb, and Johnson & Johnson. Z... |
23,819 | 2021-11-01 00:00:00 UTC | California judge rules for drugmakers in major opioid lawsuit | ABBV | https://www.nasdaq.com/articles/california-judge-rules-for-drugmakers-in-major-opioid-lawsuit-2021-11-02-0 | null | null | By Nate Raymond
Nov 1 (Reuters) - A California judge on Monday said he would rule against several large counties that accused four drugmakers of fueling an opioid epidemic, saying they had failed at trial to prove their $50 billion case.
Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding ... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. By Nate Raymond Nov 1 (Reuters) - A California judge on Mo... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. That's because "any adverse downstream consequences flowin... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. By Nate Raymond Nov 1 (Reuters) - A California judge on Mo... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. By Nate Raymond Nov 1 (Reuters) - A California judge on Mo... |
23,820 | 2021-11-01 00:00:00 UTC | California judge rules for drugmakers in major opioid lawsuit | ABBV | https://www.nasdaq.com/articles/california-judge-rules-for-drugmakers-in-major-opioid-lawsuit-2021-11-02 | null | null | Nov 1 (Reuters) - A California judge on Monday said he would rule against several large counties who accused four drugmakers of fueling an opioid epidemic, saying they had failed at trial to prove their $50 billion case.
Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. Nov 1 (Reuters) - A California judge on Monday said he wou... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. Nov 1 (Reuters) - A California judge on Monday said he wou... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. Nov 1 (Reuters) - A California judge on Monday said he wou... | Orange County Superior Court Judge Peter Wilson issued a tentative ruling finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit not liable for creating a public nuisance. Nov 1 (Reuters) - A California judge on Monday said he wou... |
23,821 | 2021-10-31 00:00:00 UTC | Best Stocks To Buy This Week? 3 Biotech Names To Know | ABBV | https://www.nasdaq.com/articles/best-stocks-to-buy-this-week-3-biotech-names-to-know-2021-10-31 | null | null | 3 Biotech Stocks To Check Out This Week
The broader stock market appears to be taking a breather after a mostly hot week fueled by earnings. Despite all this, some would argue that biotech stocks remain relevant plays in the current market. Now the slowdown in stocks is likely due to earnings letdowns from tech names s... | For instance, we could take a look at the likes of Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV). At the same time, the likes of biopharmaceutical giant AbbVie continue to break new ground on the research front. Accordingly, AbbVie lifted its profit forecasts for the fiscal year and also raised its quarterly d... | For instance, we could take a look at the likes of Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV). At the same time, the likes of biopharmaceutical giant AbbVie continue to break new ground on the research front. Accordingly, AbbVie lifted its profit forecasts for the fiscal year and also raised its quarterly d... | For instance, we could take a look at the likes of Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV). At the same time, the likes of biopharmaceutical giant AbbVie continue to break new ground on the research front. Accordingly, AbbVie lifted its profit forecasts for the fiscal year and also raised its quarterly d... | For instance, we could take a look at the likes of Gilead Sciences (NASDAQ: GILD) and AbbVie (NYSE: ABBV). At the same time, the likes of biopharmaceutical giant AbbVie continue to break new ground on the research front. Accordingly, AbbVie lifted its profit forecasts for the fiscal year and also raised its quarterly d... |
23,822 | 2021-10-30 00:00:00 UTC | FDA Approves Allergan's VUITY As First Eye Drop To Treat Presbyopia | ABBV | https://www.nasdaq.com/articles/fda-approves-allergans-vuity-as-first-eye-drop-to-treat-presbyopia-2021-10-30 | null | null | (RTTNews) - The FDA has approved Allergan's, an AbbVie (ABBV) company, VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults.
VUITY is the first and only FDA-approved eye drop to treat this common and progressive eye condition that... | (RTTNews) - The FDA has approved Allergan's, an AbbVie (ABBV) company, VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. ""We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the ... | (RTTNews) - The FDA has approved Allergan's, an AbbVie (ABBV) company, VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. ""We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the ... | ""We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the way people and their eye doctors approach presbyopia," Michael Severino, MD, Abbvie vice chairman and president said. (RTTNews) - The FDA has approved Allergan's, an AbbVie (ABBV) company, VUITY (pilocarpine HCl oph... | (RTTNews) - The FDA has approved Allergan's, an AbbVie (ABBV) company, VUITY (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. ""We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the ... |
23,823 | 2021-10-29 00:00:00 UTC | iShares Russell 1000 Growth ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-growth-etf-experiences-big-inflow-2021-10-29 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $118.6 million dollar inflow -- that's a 0.2% increase week over week in outstanding units (from 259,400,0... | Among the largest underlying components of IWF, in trading today Nike (Symbol: NKE) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 3.5%, and Eli Lilly (Symbol: LLY) is higher by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IW... | Among the largest underlying components of IWF, in trading today Nike (Symbol: NKE) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 3.5%, and Eli Lilly (Symbol: LLY) is higher by about 0.3%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price performance of IW... | Among the largest underlying components of IWF, in trading today Nike (Symbol: NKE) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 3.5%, and Eli Lilly (Symbol: LLY) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standou... | Among the largest underlying components of IWF, in trading today Nike (Symbol: NKE) is up about 0.3%, AbbVie Inc (Symbol: ABBV) is up about 3.5%, and Eli Lilly (Symbol: LLY) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standou... |
23,824 | 2021-10-29 00:00:00 UTC | Daily Dividend Report: ITW,HUM,AAPL,ROK,ABBV | ABBV | https://www.nasdaq.com/articles/daily-dividend-report%3A-itwhumaaplrokabbv-2021-10-29 | null | null | The Board of Directors of Illinois Tool Works declared a dividend on the company's common stock of $1.22 per share for the fourth quarter of 2021. The dividend equates to $4.88 per share on a full-year basis. The dividend will be paid on January 14, 2022 to shareholders of record as of December 31, 2021.
Humana announc... | This reflects an increase of approximately 8.5 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.30 per share to $1.41 per share beginni... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.30 per share to $1.41 per share beginning with the dividend payable on February 15, 2022 to shareholders of record as of January 14, 2022. This reflects an increase of approximately 8.5 percent, ... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.30 per share to $1.41 per share beginning with the dividend payable on February 15, 2022 to shareholders of record as of January 14, 2022. This reflects an increase of approximately 8.5 percent, ... | AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.30 per share to $1.41 per share beginning with the dividend payable on February 15, 2022 to shareholders of record as of January 14, 2022. Since the company's inception in 2013, AbbVie has increa... |
23,825 | 2021-10-29 00:00:00 UTC | US STOCKS-Wall Street recovers from early lows on Microsoft boost | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-street-recovers-from-early-lows-on-microsoft-boost-2021-10-29 | null | null | By Chuck Mikolajczak
NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and the S&P 500 and Nasdaq inched to fresh intraday highs on Friday as gains in Microsoft helped offset declines in Amazon and Apple after disappointing quarterly earnings from the online retailer and iPhone maker.
Microsoft's shares... | AbbVie Inc ABBV.N gained 4.2% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. "The market hasn’t overly rewarded companies that have beat expectations that have come in screamingly positive, but it has punished misses," said Liz Young, head of investment strategy at SoFi. Ma... | AbbVie Inc ABBV.N gained 4.2% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and the S&P 500 and Nasdaq inched to fresh intraday highs on Friday as gains in Microsoft helped offset declin... | AbbVie Inc ABBV.N gained 4.2% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and the S&P 500 and Nasdaq inched to fresh intraday highs on Friday as gains in Microsoft helped offset declin... | AbbVie Inc ABBV.N gained 4.2% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and the S&P 500 and Nasdaq inched to fresh intraday highs on Friday as gains in Microsoft helped offset declin... |
23,826 | 2021-10-29 00:00:00 UTC | AbbVie gets a shot in the arm from newer drug sales, lifts profit view | ABBV | https://www.nasdaq.com/articles/abbvie-gets-a-shot-in-the-arm-from-newer-drug-sales-lifts-profit-view-2021-10-29 | null | null | Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.
The company has been focusing on gaining expanded approvals and driving growth fo... | Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue. Humira is the world's highest selling medicine, accounting for nearly 40% of AbbV... | Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue. Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates o... | Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue. Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates o... | Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion. AbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62. Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profi... |
23,827 | 2021-10-29 00:00:00 UTC | US STOCKS-Wall Street shakes off Amazon, Apple weakness to end modestly higher | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-street-shakes-off-amazon-apple-weakness-to-end-modestly-higher-2021-10-29 | null | null | By Chuck Mikolajczak
NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and closed out the last trading day of the month with modest gains as a rise in Microsoft helped offset declines in Amazon and Apple after disappointing quarterly earnings from the online retailer and iPhone maker.
Microsoft's shares... | AbbVie Inc ABBV.N advanced as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. It’s the resilience of the marketplace, it suggests to me the trend is still intact," said David Joy, chief market strategist at Ameriprise Financial in Boston. Market participants have been closely a... | AbbVie Inc ABBV.N advanced as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and closed out the last trading day of the month with modest gains as a rise in Microsoft helped offset declines ... | AbbVie Inc ABBV.N advanced as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and closed out the last trading day of the month with modest gains as a rise in Microsoft helped offset declines ... | AbbVie Inc ABBV.N advanced as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. "The takeaway from today is the resilience to the overall index despite 10% of market cap in two companies disappointing and yet the market is flat. According to preliminary data, the S&P 500 .SPX gai... |
23,828 | 2021-10-29 00:00:00 UTC | US STOCKS-Wall Street shakes off Amazon, Apple weakness to end modestly higher | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-street-shakes-off-amazon-apple-weakness-to-end-modestly-higher-2021-10-29-0 | null | null | By Chuck Mikolajczak
NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and closed out the last trading day of the month with modest gains on Friday as a rise in Microsoft helped offset declines in Amazon and Apple after disappointing quarterly earnings from the online retailer and iPhone maker.
Microsof... | AbbVie Inc ABBV.N advanced 4.56% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. It’s the resilience of the marketplace, it suggests to me the trend is still intact," said David Joy, chief market strategist at Ameriprise Financial in Boston. Market participants have been clo... | AbbVie Inc ABBV.N advanced 4.56% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and closed out the last trading day of the month with modest gains on Friday as a rise in Microsoft helped ... | AbbVie Inc ABBV.N advanced 4.56% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and closed out the last trading day of the month with modest gains on Friday as a rise in Microsoft helped ... | AbbVie Inc ABBV.N advanced 4.56% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Chuck Mikolajczak NEW YORK, Oct 29 (Reuters) - U.S. stocks shook off early declines and closed out the last trading day of the month with modest gains on Friday as a rise in Microsoft helped ... |
23,829 | 2021-10-29 00:00:00 UTC | AbbVie Breaks Above 200-Day Moving Average - Bullish for ABBV | ABBV | https://www.nasdaq.com/articles/abbvie-breaks-above-200-day-moving-average-bullish-for-abbv-2021-10-29 | null | null | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.26, changing hands as high as $114.47 per share. AbbVie Inc shares are currently trading up about 4.3% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.26, changing hands as high as $114.47 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.26, changing hands as high as $114.47 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.26, changing hands as high as $114.47 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.26, changing hands as high as $114.47 per share. AbbVie Inc shares are currently trading up about 4.3% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average... |
23,830 | 2021-10-29 00:00:00 UTC | AbbVie (ABBV) Q3 2021 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q3-2021-earnings-call-transcript-2021-10-29 | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q3 2021 Earnings Call
Oct 29, 2021, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Thank you for standing by. Welcome to the AbbVie third quarter 2021earnings conference call [Operator instructions] I would n... | We also recently announced positive top-line results from a phase three study comparing our novel subcutaneous levodopa, carbidopa delivery system, ABBV-951 to oral levodopa-carbidopa in patients with advanced Parkinson's disease. AbbVie (NYSE: ABBV) Q3 2021 Earnings Call Oct 29, 2021, 9:00 a.m. Welcome to the AbbVie t... | Operator [Operator signoff] Duration: 86 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vice... | Operator [Operator signoff] Duration: 86 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vice... | Operator [Operator signoff] Duration: 86 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Mike Severino -- Vice Chairman and President Rob Michael -- Executive Vice... |
23,831 | 2021-10-29 00:00:00 UTC | US STOCKS-Microsoft brings S&P 500, Nasdaq back into record territory | ABBV | https://www.nasdaq.com/articles/us-stocks-microsoft-brings-sp-500-nasdaq-back-into-record-territory-2021-10-29 | null | null | By Devik Jain and Shashank Nayar
Oct 29 (Reuters) - The S&P 500 and the Nasdaq crept back up to record territory on Friday after a boost from Microsoft, which overtook Apple Inc as the world's most valuable company after the iPhone maker posted downbeat quarterly revenue on hit from supply chain disruptions.
Wall Stree... | AbbVie Inc ABBV.N gained 4.1% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq crept back up to record territory on Friday after a boost from Microsoft, which overtook Apple Inc as the world's most... | AbbVie Inc ABBV.N gained 4.1% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq crept back up to record territory on Friday after a boost from Microsoft, which overtook Apple Inc as the world's most... | AbbVie Inc ABBV.N gained 4.1% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq crept back up to record territory on Friday after a boost from Microsoft, which overtook Apple Inc as the world's most... | AbbVie Inc ABBV.N gained 4.1% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq crept back up to record territory on Friday after a boost from Microsoft, which overtook Apple Inc as the world's most... |
23,832 | 2021-10-29 00:00:00 UTC | AbbVie Q3 21 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q3-21-earnings-conference-call-at-9%3A00-am-et-2021-10-29 | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 29, 2021, to discuss Q3 21 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 29, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 29, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 29, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on October 29, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... |
23,833 | 2021-10-29 00:00:00 UTC | AbbVie Q3 adjusted earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q3-adjusted-earnings-beat-estimates-2021-10-29 | null | null | (RTTNews) - AbbVie (ABBV) announced earnings for its third quarter that advanced from the same period last year.
The company's profit totaled $3.18 billion, or $1.78 per share. This compares with $2.31 billion, or $1.29 per share, in last year's third quarter.
Excluding items, AbbVie reported adjusted earnings of $5.95... | (RTTNews) - AbbVie (ABBV) announced earnings for its third quarter that advanced from the same period last year. Excluding items, AbbVie reported adjusted earnings of $5.95 billion or $3.33 per share for the period. AbbVie earnings at a glance: -Earnings (Q3): $5.95 Bln. | Excluding items, AbbVie reported adjusted earnings of $5.95 billion or $3.33 per share for the period. (RTTNews) - AbbVie (ABBV) announced earnings for its third quarter that advanced from the same period last year. AbbVie earnings at a glance: -Earnings (Q3): $5.95 Bln. | (RTTNews) - AbbVie (ABBV) announced earnings for its third quarter that advanced from the same period last year. Excluding items, AbbVie reported adjusted earnings of $5.95 billion or $3.33 per share for the period. AbbVie earnings at a glance: -Earnings (Q3): $5.95 Bln. | Excluding items, AbbVie reported adjusted earnings of $5.95 billion or $3.33 per share for the period. (RTTNews) - AbbVie (ABBV) announced earnings for its third quarter that advanced from the same period last year. AbbVie earnings at a glance: -Earnings (Q3): $5.95 Bln. |
23,834 | 2021-10-29 00:00:00 UTC | US STOCKS-Apple, Amazon set to knock S&P 500, Nasdaq off record peak | ABBV | https://www.nasdaq.com/articles/us-stocks-apple-amazon-set-to-knock-sp-500-nasdaq-off-record-peak-2021-10-29 | null | null | By Devik Jain and Shashank Nayar
Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes looked set to drop from record highs on Friday, as results from mega-cap firms Apple and Amazon.com reignited concerns of labor and supply shortages that have been at the forefront of this quarterly earnings season.
Market participan... | AbbVie Inc ABBV.N gained 2.7% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes looked set to drop from record highs on Friday, as results from mega-cap firms Apple and Amazon.com reignited ... | AbbVie Inc ABBV.N gained 2.7% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes looked set to drop from record highs on Friday, as results from mega-cap firms Apple and Amazon.com reignited ... | AbbVie Inc ABBV.N gained 2.7% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes looked set to drop from record highs on Friday, as results from mega-cap firms Apple and Amazon.com reignited ... | AbbVie Inc ABBV.N gained 2.7% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes looked set to drop from record highs on Friday, as results from mega-cap firms Apple and Amazon.com reignited ... |
23,835 | 2021-10-29 00:00:00 UTC | US STOCKS-Apple, Amazon knock S&P 500, Nasdaq off record peak; Caterpillar lifts Dow | ABBV | https://www.nasdaq.com/articles/us-stocks-apple-amazon-knock-sp-500-nasdaq-off-record-peak-caterpillar-lifts-dow-2021-10 | null | null | By Devik Jain and Shashank Nayar
Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes dropped from their record highs on Friday after dismal results from mega-cap firms Apple and Amazon.com, while gains in Chevron and Caterpillar helped the blue-chip Dow outperform.
Market participants have been closely watching how c... | AbbVie Inc ABBV.N gained 3.8% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes dropped from their record highs on Friday after dismal results from mega-cap firms Apple and Amazon.com, while... | AbbVie Inc ABBV.N gained 3.8% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes dropped from their record highs on Friday after dismal results from mega-cap firms Apple and Amazon.com, while... | AbbVie Inc ABBV.N gained 3.8% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes dropped from their record highs on Friday after dismal results from mega-cap firms Apple and Amazon.com, while... | AbbVie Inc ABBV.N gained 3.8% as the U.S. drugmaker raised its 2021 adjusted profit forecast for the third time this year. By Devik Jain and Shashank Nayar Oct 29 (Reuters) - The S&P 500 and the Nasdaq indexes dropped from their record highs on Friday after dismal results from mega-cap firms Apple and Amazon.com, while... |
23,836 | 2021-10-29 00:00:00 UTC | What To Expect From Merck's Q3? | ABBV | https://www.nasdaq.com/articles/what-to-expect-from-mercks-q3-2021-10-29 | null | null | Merck (NYSE: MRK) is scheduled to report its Q3 2021 results on Thursday, October 28. We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-19 delta variant likely impacted the company’s overall vaccine sales growth, including that for Gardasil. That said, the o... | While we expect the revenue and earnings to fall below the consensus estimates, our forecast indicates that Merck’s valuation is $91 per share, which is 12% above the current market price of around $81, implying that MRK stock still has some room for growth. The company’s animal health business has also been doing well... | We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-19 delta variant likely impacted the company’s overall vaccine sales growth, including that for Gardasil. (1) Revenues expected to be below the consensus estimates Trefis estimates Merck’s Q3 2021 revenues to... | While we expect the revenue and earnings to fall below the consensus estimates, our forecast indicates that Merck’s valuation is $91 per share, which is 12% above the current market price of around $81, implying that MRK stock still has some room for growth. (1) Revenues expected to be below the consensus estimates Tre... | We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-19 delta variant likely impacted the company’s overall vaccine sales growth, including that for Gardasil. While we expect the revenue and earnings to fall below the consensus estimates, our forecast indicates... |
23,837 | 2021-10-29 00:00:00 UTC | Friday Sector Leaders: Healthcare, Technology & Communications | ABBV | https://www.nasdaq.com/articles/friday-sector-leaders%3A-healthcare-technology-communications-2021-10-29 | null | null | The best performing sector as of midday Friday is the Healthcare sector, higher by 0.4%. Within that group, DexCom Inc (Symbol: DXCM) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 8.3% and 4.6%, respectively. Among healthcare ETFs, one ETF following the sector is the Health Care ... | Combined, DXCM and ABBV make up approximately 5.0% of the underlying holdings of XLV. Within that group, DexCom Inc (Symbol: DXCM) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 8.3% and 4.6%, respectively. DexCom Inc, meanwhile, is up 67.08% year-to-date, and AbbVie Inc is up 11.... | Within that group, DexCom Inc (Symbol: DXCM) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 8.3% and 4.6%, respectively. DexCom Inc, meanwhile, is up 67.08% year-to-date, and AbbVie Inc is up 11.89% year-to-date. Combined, DXCM and ABBV make up approximately 5.0% of the underlying... | Within that group, DexCom Inc (Symbol: DXCM) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 8.3% and 4.6%, respectively. DexCom Inc, meanwhile, is up 67.08% year-to-date, and AbbVie Inc is up 11.89% year-to-date. Combined, DXCM and ABBV make up approximately 5.0% of the underlying... | Within that group, DexCom Inc (Symbol: DXCM) and AbbVie Inc (Symbol: ABBV) are two large stocks leading the way, showing a gain of 8.3% and 4.6%, respectively. DexCom Inc, meanwhile, is up 67.08% year-to-date, and AbbVie Inc is up 11.89% year-to-date. Combined, DXCM and ABBV make up approximately 5.0% of the underlying... |
23,838 | 2021-10-29 00:00:00 UTC | AbbVie Raises FY21 Outlook; Boosts Dividend 8.5% - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-raises-fy21-outlook-boosts-dividend-8.5-quick-facts-2021-10-29 | null | null | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2021.
For fiscal 2021, AbbVie now projects earnings in a range of $6.29 to $6.33 per share and adjusted earnings in a range of $12.63 to $12... | (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2021. Further, AbbVie announced that its board of directors declared a 8.5 percent higher quarterly cash dividend of $1.41 per share, beginn... | For fiscal 2021, AbbVie now projects earnings in a range of $6.29 to $6.33 per share and adjusted earnings in a range of $12.63 to $12.67 per share. (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the f... | For fiscal 2021, AbbVie now projects earnings in a range of $6.29 to $6.33 per share and adjusted earnings in a range of $12.63 to $12.67 per share. (RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) raised its adjusted earnings guidance for the f... | Further, AbbVie announced that its board of directors declared a 8.5 percent higher quarterly cash dividend of $1.41 per share, beginning with the dividend payable on February 15, 2022 to shareholders of record as of January 14, 2022. (RTTNews) - While reporting financial results for the third quarter on Friday, biopha... |
23,839 | 2021-10-29 00:00:00 UTC | AbbVie gets a shot in the arm from newer drug sales, lifts profit view | ABBV | https://www.nasdaq.com/articles/abbvie-gets-a-shot-in-the-arm-from-newer-drug-sales-lifts-profit-view-2021-10-29-0 | null | null | Compares profit with estimates, adds share prices
Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly profit and revenue.
The company has been... | Humira is the world's highest selling medicine, accounting for nearly 40% of AbbVie's total sales. Compares profit with estimates, adds share prices Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newe... | Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion. AbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62. Compares profit with estimates, adds share prices Oct 29 (Reuters) - U.S. drugmaker AbbVie I... | Compares profit with estimates, adds share prices Oct 29 (Reuters) - U.S. drugmaker AbbVie Inc ABBV.N on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly profit and revenue. Total sales for AbbV... | Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion. AbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62. Compares profit with estimates, adds share prices Oct 29 (Reuters) - U.S. drugmaker AbbVie I... |
23,840 | 2021-10-29 00:00:00 UTC | AbbVie Says Cariprazine Met Primary Endpoint In Phase 3 Study For Major Depressive Disorder | ABBV | https://www.nasdaq.com/articles/abbvie-says-cariprazine-met-primary-endpoint-in-phase-3-study-for-major-depressive | null | null | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD).
In Study 3111-... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD). Based on the p... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD). Based on the p... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD). Based on the p... | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced Friday top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating the efficacy and safety of cariprazine (Vraylar) as an adjunctive treatment for patients with major depressive disorder (MDD). Based on the p... |
23,841 | 2021-10-29 00:00:00 UTC | AbbVie’s ABBV-951 Phase 3 Study Reflects Optimism; Shares Rise | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-951-phase-3-study-reflects-optimism-shares-rise-2021-10-29 | null | null | Shares of AbbVie (ABBV) rose 1.2% to close at $109.67 on Thursday after the biopharmaceutical company study revealed the results of the Phase 3 study of ABBV-951, an investigational therapy.
The results showed that continuous, subcutaneous infusion of ABBV-951 met its primary endpoint. (See Insiders’ Hot Stocks on TipR... | (See Insiders’ Hot Stocks on TipRanks) Notably, the study compared the efficacy, safety and tolerability profile of ABBV-951 (foslevodopa/foscarbidopa) to oral levodopa/carbidopa in advanced Parkinson’s disease (PD) patients. Shares of AbbVie (ABBV) rose 1.2% to close at $109.67 on Thursday after the biopharmaceutical ... | The average AbbVie price target of $129.58 implies 18.2% upside potential from current levels. Bloggers Weigh In TipRanks data shows that financial blogger opinions are 100% Bullish on AbbVie, compared to a sector average of 70%. Shares of AbbVie (ABBV) rose 1.2% to close at $109.67 on Thursday after the biopharmaceuti... | (See Insiders’ Hot Stocks on TipRanks) Notably, the study compared the efficacy, safety and tolerability profile of ABBV-951 (foslevodopa/foscarbidopa) to oral levodopa/carbidopa in advanced Parkinson’s disease (PD) patients. VC of AbbVie, Michael Severino, said, “Parkinson’s disease is a progressive, irreversible neur... | Shares of AbbVie (ABBV) rose 1.2% to close at $109.67 on Thursday after the biopharmaceutical company study revealed the results of the Phase 3 study of ABBV-951, an investigational therapy. The results showed that continuous, subcutaneous infusion of ABBV-951 met its primary endpoint. (See Insiders’ Hot Stocks on TipR... |
23,842 | 2021-10-28 00:00:00 UTC | AbbVie: Phase 3 Trial Of ABBV-951 Shows Improvement In Motor Fluctuations In Parkinson's Disease | ABBV | https://www.nasdaq.com/articles/abbvie%3A-phase-3-trial-of-abbv-951-shows-improvement-in-motor-fluctuations-in-parkinsons | null | null | (RTTNews) - AbbVie (ABBV) said ABBV-951 (Foslevodopa/Foscarbidopa) showed improvement in controlling motor fluctuations compared to oral Levodopa/Carbidopa medication in pivotal phase 3 trial in patients with advanced Parkinson's Disease.
The pivotal Phase 3, randomized, double-blind, double-dummy, active-controlled st... | (RTTNews) - AbbVie (ABBV) said ABBV-951 (Foslevodopa/Foscarbidopa) showed improvement in controlling motor fluctuations compared to oral Levodopa/Carbidopa medication in pivotal phase 3 trial in patients with advanced Parkinson's Disease. The company stated that patients who received 24 hours/daily ABBV-951 showed stat... | (RTTNews) - AbbVie (ABBV) said ABBV-951 (Foslevodopa/Foscarbidopa) showed improvement in controlling motor fluctuations compared to oral Levodopa/Carbidopa medication in pivotal phase 3 trial in patients with advanced Parkinson's Disease. The pivotal Phase 3, randomized, double-blind, double-dummy, active-controlled st... | (RTTNews) - AbbVie (ABBV) said ABBV-951 (Foslevodopa/Foscarbidopa) showed improvement in controlling motor fluctuations compared to oral Levodopa/Carbidopa medication in pivotal phase 3 trial in patients with advanced Parkinson's Disease. The pivotal Phase 3, randomized, double-blind, double-dummy, active-controlled st... | (RTTNews) - AbbVie (ABBV) said ABBV-951 (Foslevodopa/Foscarbidopa) showed improvement in controlling motor fluctuations compared to oral Levodopa/Carbidopa medication in pivotal phase 3 trial in patients with advanced Parkinson's Disease. The company stated that patients who received 24 hours/daily ABBV-951 showed stat... |
23,843 | 2021-10-28 00:00:00 UTC | What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report | ABBV | https://www.nasdaq.com/articles/what-investors-should-pay-attention-to-in-abbvies-q3-earnings-report-2021-10-28 | null | null | With AbbVie's (NYSE: ABBV) third-quarter earnings report scheduled for Oct. 29, shareholders and prospective investors should be on alert. AbbVie is in the middle of transitioning its revenue base away from dependence on its blockbuster drug Humira, as its exclusivity protections are starting to expire outside the U.S.... | If in the earnings report, domestic growth is even slower than that or if international sales start to collapse even faster, it could spell serious short-term trouble, as the market's appraisal of AbbVie's future revenue will dim even more. With AbbVie's (NYSE: ABBV) third-quarter earnings report scheduled for Oct. 29,... | As the world's leading immunology drug, AbbVie's Humira is approved for no fewer than 16 different indications in dermatology and other specialty areas. With AbbVie's (NYSE: ABBV) third-quarter earnings report scheduled for Oct. 29, shareholders and prospective investors should be on alert. AbbVie is in the middle of t... | AbbVie is in the middle of transitioning its revenue base away from dependence on its blockbuster drug Humira, as its exclusivity protections are starting to expire outside the U.S. That means the company's stock is in a particularly sensitive time, as the prospective replacements for Humira are still in the process of... | With AbbVie's (NYSE: ABBV) third-quarter earnings report scheduled for Oct. 29, shareholders and prospective investors should be on alert. AbbVie is in the middle of transitioning its revenue base away from dependence on its blockbuster drug Humira, as its exclusivity protections are starting to expire outside the U.S.... |
23,844 | 2021-10-28 00:00:00 UTC | Pre-Market Earnings Report for October 29, 2021 : XOM, CVX, ABBV, CHTR, AON, CL, LHX, PSX, LYB, WY, IMO, GWW | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-october-29-2021-%3A-xom-cvx-abbv-chtr-aon-cl-lhx-psx-lyb-wy | null | null | The following companies are expected to report earnings prior to market open on 10/29/2021. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending September 30, 2021. The oil company's consensus earnings per share forecast from the 8 ... | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.58 vs. an industry ratio of 15.70. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.58 vs. an industry ratio of 15.70. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.58 vs. an industry ratio of 15.70. | AbbVie Inc. (ABBV)is reporting for the quarter ending September 30, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 8.58 vs. an industry ratio of 15.70. |
23,845 | 2021-10-28 00:00:00 UTC | Should Investors Worry About AbbVie? | ABBV | https://www.nasdaq.com/articles/should-investors-worry-about-abbvie-2021-10-28 | null | null | Pharmaceutical giant AbbVie (NYSE: ABBV) has built a good business on its long-running exclusivity of the world's top-selling drug, Humira, used for treating arthritis. However, Humira will lose its patent protection in 2023, and a handful of biosimilars -- that is, "copy cat" versions of the drug made by competitors w... | Pharmaceutical giant AbbVie (NYSE: ABBV) has built a good business on its long-running exclusivity of the world's top-selling drug, Humira, used for treating arthritis. As long as AbbVie can do a solid job replacing lost Humira sales, the company should have little issue continuing to pay a large dividend while develop... | AbbVie also made a significant acquisition, buying pharmaceutical company Allergan last year for $63 billion. Analysts estimate AbbVie's full-year 2021 earnings per share will be $12.60, giving the stock a P/E ratio of just under nine. Pharmaceutical giant AbbVie (NYSE: ABBV) has built a good business on its long-runni... | As long as AbbVie can do a solid job replacing lost Humira sales, the company should have little issue continuing to pay a large dividend while developing new drugs in its pipeline. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. Pharmaceutical giant AbbVi... | AbbVie also made a significant acquisition, buying pharmaceutical company Allergan last year for $63 billion. Analysts estimate AbbVie's full-year 2021 earnings per share will be $12.60, giving the stock a P/E ratio of just under nine. Pharmaceutical giant AbbVie (NYSE: ABBV) has built a good business on its long-runni... |
23,846 | 2021-10-28 00:00:00 UTC | ABBV December 10th Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-december-10th-options-begin-trading-2021-10-28 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 10th contracts and identified one put and one call contract of particular interest.
The put... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $112.00 strike highlighted in red: Considering the fact that the $112.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $100.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $112.00 strike price has a current bid of $1.91. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 10th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $112.00 strike highlighted in red: Consi... |
23,847 | 2021-10-27 00:00:00 UTC | AbbVie Takes Another Step Toward Its Post-Humira Future | ABBV | https://www.nasdaq.com/articles/abbvie-takes-another-step-toward-its-post-humira-future-2021-10-27 | null | null | Since AbbVie (NYSE: ABBV) began trading in December 2012, it has left the S&P 500 in the dust. AbbVie has outperformed the S&P 500 by nearly 60% in the past nine years. Most of the returns that AbbVie has generated for its shareholders have come from its top-selling drug in the world, Humira, which has grown sales from... | Even for a pharma stock such as AbbVie that analysts expect will generate $56.3 billion in revenue this year, a blockbuster indication like PsA for Skyrizi is a meaningful boost. Since AbbVie (NYSE: ABBV) began trading in December 2012, it has left the S&P 500 in the dust. AbbVie has outperformed the S&P 500 by nearly ... | Noting insurance adjustments, AbbVie will likely receive $20,000 in annual revenue per patient for Skyrizi, which equates to $1 billion in annual sales potential for a PsA indication. Even for a pharma stock such as AbbVie that analysts expect will generate $56.3 billion in revenue this year, a blockbuster indication l... | Noting insurance adjustments, AbbVie will likely receive $20,000 in annual revenue per patient for Skyrizi, which equates to $1 billion in annual sales potential for a PsA indication. Since AbbVie (NYSE: ABBV) began trading in December 2012, it has left the S&P 500 in the dust. AbbVie has outperformed the S&P 500 by ne... | Noting insurance adjustments, AbbVie will likely receive $20,000 in annual revenue per patient for Skyrizi, which equates to $1 billion in annual sales potential for a PsA indication. Since AbbVie was spun off from Abbott Laboratories (NYSE: ABT), AbbVie has raised its dividend each year. Since AbbVie (NYSE: ABBV) bega... |
23,848 | 2021-10-27 00:00:00 UTC | 3 Stocks You Can Still Buy on Sale in a Ridiculously Expensive Market | ABBV | https://www.nasdaq.com/articles/3-stocks-you-can-still-buy-on-sale-in-a-ridiculously-expensive-market-2021-10-27 | null | null | Most stocks are priced at a premium right now. Wall Street knows it. I know it. You know it. In fact, the Shiller cyclically adjusted price-to-earnings (CAPE) ratio is at its highest level since early 2000 during the heady dot-com days.
But that doesn't mean that every stock is trading at a nosebleed level. Here are th... | The acquisition of Allergan brought growth drivers including antipsychotic Vraylar and migraine drug Ubrelvy into AbbVie's lineup. AbbVie AbbVie's (NYSE: ABBV) shares currently trade at close to 7.9 times expected earnings. To be sure, there's a reason why AbbVie is cheap. | AbbVie AbbVie's (NYSE: ABBV) shares currently trade at close to 7.9 times expected earnings. To be sure, there's a reason why AbbVie is cheap. The autoimmune disease drug generated 36% of AbbVie's total revenue in the second quarter. | See the 10 stocks *Stock Advisor returns as of October 20, 2021 Keith Speights owns shares of AbbVie, Enterprise Products Partners, and Viatris Inc. AbbVie AbbVie's (NYSE: ABBV) shares currently trade at close to 7.9 times expected earnings. To be sure, there's a reason why AbbVie is cheap. | With these and other products plus pipeline candidates on the way, AbbVie should be able to deliver solid growth throughout this decade except in 2023. AbbVie AbbVie's (NYSE: ABBV) shares currently trade at close to 7.9 times expected earnings. To be sure, there's a reason why AbbVie is cheap. |
23,849 | 2021-10-26 00:00:00 UTC | Was Atea Pharmaceutical's Flop Predictable? | ABBV | https://www.nasdaq.com/articles/was-atea-pharmaceuticals-flop-predictable-2021-10-26 | null | null | This month, as Merck (NYSE: MRK) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19, Atea Pharmaceuticals (NASDAQ: AVIR) stock saw a significant drop. Unfortunately, investors are unlikely to see the small-cap biotech replicate Moderna's success as the next COVID-19 underd... | Unfortunately, this does not significantly differentiate the product from AbbVie's Mavyret, which sold $442 million in the most recent quarter and also uses an eight-week treatment period. This month, as Merck (NYSE: MRK) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19,... | Unfortunately, this does not significantly differentiate the product from AbbVie's Mavyret, which sold $442 million in the most recent quarter and also uses an eight-week treatment period. Let's look at a different company that has come under fire for its therapy and clinical trials: Biogen (NASDAQ: BIIB) and its Alzhe... | Unfortunately, this does not significantly differentiate the product from AbbVie's Mavyret, which sold $442 million in the most recent quarter and also uses an eight-week treatment period. In the Merck trial, having at least one underlying risk factor associated with worse clinical outcomes was a requirement to be enro... | Unfortunately, this does not significantly differentiate the product from AbbVie's Mavyret, which sold $442 million in the most recent quarter and also uses an eight-week treatment period. Atea included vaccinated patients in its trial, whereas the mega pharma did not enroll vaccinated patients. It does have a hepatiti... |
23,850 | 2021-10-25 00:00:00 UTC | Bausch, Clearside receive U.S. approval for eye injection | ABBV | https://www.nasdaq.com/articles/bausch-clearside-receive-u.s.-approval-for-eye-injection-2021-10-25 | null | null | Oct 25 (Reuters) - Bausch Health Companies Inc BHC.TO and Clearside Biomedical Inc CLSD.O said on Monday they received approval from the U.S. health regulator for their eye injection, giving patients access to a novel treatment for vision loss resulting from an inflammatory eye condition.
The drug, Xipere, is injected ... | Other drugs used to treat the condition in the United States include Bristol Myers Squibb's BMY.N Kenalog, administered near the eye and AbbVie Inc's ABBV.N Ozurdex eye implant. Xipere achieved its main goal in Clearside's late-stage study, with nearly half the patients on the treatment showing improvement in the clari... | Other drugs used to treat the condition in the United States include Bristol Myers Squibb's BMY.N Kenalog, administered near the eye and AbbVie Inc's ABBV.N Ozurdex eye implant. With Xipere, high levels of medication can be delivered to target tissues, such as the retina and the drug can treat the swelling, leading to ... | Other drugs used to treat the condition in the United States include Bristol Myers Squibb's BMY.N Kenalog, administered near the eye and AbbVie Inc's ABBV.N Ozurdex eye implant. Oct 25 (Reuters) - Bausch Health Companies Inc BHC.TO and Clearside Biomedical Inc CLSD.O said on Monday they received approval from the U.S. ... | Other drugs used to treat the condition in the United States include Bristol Myers Squibb's BMY.N Kenalog, administered near the eye and AbbVie Inc's ABBV.N Ozurdex eye implant. Oct 25 (Reuters) - Bausch Health Companies Inc BHC.TO and Clearside Biomedical Inc CLSD.O said on Monday they received approval from the U.S. ... |
23,851 | 2021-10-25 00:00:00 UTC | What Could These Clinical Results Mean for AbbVie's Shareholders? | ABBV | https://www.nasdaq.com/articles/what-could-these-clinical-results-mean-for-abbvies-shareholders-2021-10-25 | null | null | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. But what impact could these clinical results have on pharma stock AbbVie in the years ahead?
Let's dive into th... | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. AbbVie enrolled 420 adult patients with ankylosing spondylitis who previously failed at least one biologic dise... | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. But what impact could these clinical results have on pharma stock AbbVie in the years ahead? AbbVie enrolled 42... | Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing spondylitis. AbbVie enrolled 420 adult patients with ankylosing spondylitis who previously failed at least one biologic dise... | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie and Abbott Laboratories. Earlier this month, AbbVie (NYSE: ABBV) announced promising top-line results from a phase 3 study examining the efficacy and safety of Rinvoq in treating patients diagnosed with active ankylosing... |
23,852 | 2021-10-21 00:00:00 UTC | Progenity Has Seven Quarters Left to Reverse Its Burn Rate | ABBV | https://www.nasdaq.com/articles/progenity-has-seven-quarters-left-to-reverse-its-burn-rate-2021-10-21 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Progenity (NASDAQ:PROG) is a San Diego-based biotech company that specializes in gastrointestinal health and oral biotherapeutics. Right now the company has no real revenue to speak of and is burning through cash. If Progenity can cut its burn rate, PROG st... | For example, Progenity is working closely with AbbVie (NYSE:ABBV). Progenity also has a capsule for one of Novo Nordisk’s (NYSE:NVO) drugs called Saxenda (for excess weight loss) and Victoza (for Type 2 diabetes). If the company can show that revenue is rising and its ongoing negative cash flow is improving, it’s possi... | For example, Progenity is working closely with AbbVie (NYSE:ABBV). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Progenity (NASDAQ:PROG) is a San Diego-based biotech company that specializes in gastrointestinal health and oral biotherapeutics. These patents relate to drug delivery, GI (gastrointestinal... | For example, Progenity is working closely with AbbVie (NYSE:ABBV). Cash Burn at Progenity The problem the company has is its huge cash burn rate until one of its patents starts to produce large amounts of revenue. It had $66 million in cash and raised it by another $60 million to $126 million. | For example, Progenity is working closely with AbbVie (NYSE:ABBV). Cash Burn at Progenity The problem the company has is its huge cash burn rate until one of its patents starts to produce large amounts of revenue. In the last six months, according to the latest 10-Q, Progenity had a loss in cash flow from operations of... |
23,853 | 2021-10-21 00:00:00 UTC | Top Dividend Stocks To Buy In 2021? 3 In Focus | ABBV | https://www.nasdaq.com/articles/top-dividend-stocks-to-buy-in-2021-3-in-focus-2021-10-21 | null | null | 3 Dividend Stocks Worth Checking Out Right Now
With all the focus on earnings and an improving job market, thestock market todayis filled with upbeat news. Regardless, some would argue that investors should not overlook dividend stocks as well. For the most part, this would be due to rising concerns over inflation as t... | For this reason, it is important to have multiple treatment options available for physicians to effectively manage their patients’ condition,” said Thomas Hudson, senior vice president, research and development, AbbVie. “The CHMP’s recommendation to approve risankizumab in psoriatic arthritis is an important step in br... | Top Dividend Stocks To Buy [Or Sell] Ahead Of November 2021 Apple Inc. (NASDAQ: AAPL) Coca-Cola Company (NYSE: KO) AbbVie Inc. (NYSE: ABBV) Apple Inc. Apple is a multinational technology that specializes in consumer electronics and online services. “The CHMP’s recommendation to approve risankizumab in psoriatic arthrit... | Top Dividend Stocks To Buy [Or Sell] Ahead Of November 2021 Apple Inc. (NASDAQ: AAPL) Coca-Cola Company (NYSE: KO) AbbVie Inc. (NYSE: ABBV) Apple Inc. Apple is a multinational technology that specializes in consumer electronics and online services. 4 Consumer Stocks To Consider AbbVie Inc. Next, we have AbbVie, a bioph... | Top Dividend Stocks To Buy [Or Sell] Ahead Of November 2021 Apple Inc. (NASDAQ: AAPL) Coca-Cola Company (NYSE: KO) AbbVie Inc. (NYSE: ABBV) Apple Inc. Apple is a multinational technology that specializes in consumer electronics and online services. 4 Consumer Stocks To Consider AbbVie Inc. Next, we have AbbVie, a bioph... |
23,854 | 2021-10-21 00:00:00 UTC | HDV, ABBV, BMY, TFC: ETF Outflow Alert | ABBV | https://www.nasdaq.com/articles/hdv-abbv-bmy-tfc%3A-etf-outflow-alert-2021-10-21 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core High Dividend ETF (Symbol: HDV) where we have detected an approximate $93.1 million dollar outflow -- that's a 1.2% decrease week over week (from 76,500,000 to 75,550,000). Amon... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.5%, and Truist Financial Corp (Symbol: TFC) is higher by about 0.1%. For a complete list of holdings, visit the HDV Holdings page » The chart below shows ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.5%, and Truist Financial Corp (Symbol: TFC) is higher by about 0.1%. For a complete list of holdings, visit the HDV Holdings page » The chart below shows ... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.5%, and Truist Financial Corp (Symbol: TFC) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs... | Among the largest underlying components of HDV, in trading today AbbVie Inc (Symbol: ABBV) is down about 0.8%, Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.5%, and Truist Financial Corp (Symbol: TFC) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs... |
23,855 | 2021-10-21 00:00:00 UTC | Could This Be the Next Blockbuster Indication for Eli Lilly? | ABBV | https://www.nasdaq.com/articles/could-this-be-the-next-blockbuster-indication-for-eli-lilly-2021-10-21 | null | null | Eli Lilly (NYSE: LLY) and Incyte's (NASDAQ: INCY) drug, Olumiant, has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to treat hospitalized COVID-19 patients with or without remdesivir. While the EUAs for Olumiant to be used as both a monotherapy or a combination therapy with... | A move from the FDA last month required Janus kinase (JAK) inhibitors such as Olumiant and AbbVie's (NYSE: ABBV) Rinvoq to carry a warning label disclosing serious potential side effects, such as cancer and blood clots. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie ... | A move from the FDA last month required Janus kinase (JAK) inhibitors such as Olumiant and AbbVie's (NYSE: ABBV) Rinvoq to carry a warning label disclosing serious potential side effects, such as cancer and blood clots. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie ... | A move from the FDA last month required Janus kinase (JAK) inhibitors such as Olumiant and AbbVie's (NYSE: ABBV) Rinvoq to carry a warning label disclosing serious potential side effects, such as cancer and blood clots. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie ... | A move from the FDA last month required Janus kinase (JAK) inhibitors such as Olumiant and AbbVie's (NYSE: ABBV) Rinvoq to carry a warning label disclosing serious potential side effects, such as cancer and blood clots. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie ... |
23,856 | 2021-10-20 00:00:00 UTC | Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | ABBV | https://www.nasdaq.com/articles/could-this-beaten-down-biotech-stock-be-the-next-buyout-target-2021-10-20 | null | null | What do AbbVie, Bristol Myers Squibb, and AstraZeneca all have in common? All three are among the largest pharma companies in the world. But all of these drugmakers have also closed high-profile acquisitions within the past two years. These deals helped them bolster their lineups and deepen their pipelines, among other... | What do AbbVie, Bristol Myers Squibb, and AstraZeneca all have in common? First, the company's Biologics License Application (BLA) in the U.S. for LentiGlobin as a potential treatment for transfusion-dependent beta-thalassemia (TDT, a rare blood-related disorder) was delayed. The company had initially planned to comple... | What do AbbVie, Bristol Myers Squibb, and AstraZeneca all have in common? Promising gene-editing platform Bluebird has earned several regulatory approvals for its gene-editing therapies. Since the company exited the European market, so it won't generate revenue from those approved products there. | What do AbbVie, Bristol Myers Squibb, and AstraZeneca all have in common? With that in mind, let's look at a biotech company that could become a buyout target within the next couple of years, Bluebird Bio (NASDAQ: BLUE). While three regulatory approvals isn't a big deal for larger biotechs, for a company the size of Bl... | What do AbbVie, Bristol Myers Squibb, and AstraZeneca all have in common? First, the company's Biologics License Application (BLA) in the U.S. for LentiGlobin as a potential treatment for transfusion-dependent beta-thalassemia (TDT, a rare blood-related disorder) was delayed. Promising gene-editing platform Bluebird ha... |
23,857 | 2021-10-19 00:00:00 UTC | FDA OKs Cyltezo As First Interchangeable Biosimilar To Humira | ABBV | https://www.nasdaq.com/articles/fda-oks-cyltezo-as-first-interchangeable-biosimilar-to-humira-2021-10-19 | null | null | (RTTNews) - The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses.
Cylt... | Boehringer Ingelheim, along with five other Humira biosimilar maker's, settled with AbbVie for launch dates in 2023 due to patent protections. (RTTNews) - The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or ad... | (RTTNews) - The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Boehringer Ingelheim, along with five other Humira biosimilar maker's, settled with AbbVie for launch dates in 2023 due to patent pro... | (RTTNews) - The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Boehringer Ingelheim, along with five other Humira biosimilar maker's, settled with AbbVie for launch dates in 2023 due to patent pro... | (RTTNews) - The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Boehringer Ingelheim, along with five other Humira biosimilar maker's, settled with AbbVie for launch dates in 2023 due to patent pro... |
23,858 | 2021-10-19 00:00:00 UTC | 3 Leading Healthcare Stocks to Buy in 2021 and Beyond | ABBV | https://www.nasdaq.com/articles/3-leading-healthcare-stocks-to-buy-in-2021-and-beyond-2021-10-19 | null | null | Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth.
ResMed is already an industry leader in sleep apnea therapies, an area that's expected to grow as our population ages. Walgreens Boots Alliance is jumping onto the ... | Walgreens Boots Alliance is jumping onto the trend toward value-oriented healthcare services, and AbbVie's huge stable of drugs and pipeline give it a diversity that protects its long-term outlook. Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clea... | Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth. Through the last six months, AbbVie reported net revenue of $26.9 billion, up 41.2% year over year. Walgreens Boots Alliance is jumping onto the trend toward value-... | Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth. Walgreens Boots Alliance is jumping onto the trend toward value-oriented healthcare services, and AbbVie's huge stable of drugs and pipeline give it a diversity tha... | Through the last six months, AbbVie reported net revenue of $26.9 billion, up 41.2% year over year. Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth. Walgreens Boots Alliance is jumping onto the trend toward value-... |
23,859 | 2021-10-18 00:00:00 UTC | 2 Best Biotech Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-best-biotech-stocks-to-buy-right-now-2021-10-18 | null | null | It's no secret that it has progressively become more difficult for investors to find high-yield investments these days. After all, the current 1.3% yield of the S&P 500 isn't that far off the 1.1% yield of the index leading up to the dot-com bubble that occurred two decades ago.
Frothy market valuations can lead income... | Merck is best known for the second best-selling drug in the world, Keytruda, behind AbbVie's (NYSE: ABBV) immunology drug, Humira. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, and Merck & Co. Amgen's top-selling drug... | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, and Merck & Co. Merck is best known for the second best-selling drug in the world, Keytruda, behind AbbVie's (NYSE: ABBV) immunology drug, Humira. Since Acceleron Pharma w... | Merck is best known for the second best-selling drug in the world, Keytruda, behind AbbVie's (NYSE: ABBV) immunology drug, Humira. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, and Merck & Co. Amgen's top-selling drug... | Merck is best known for the second best-selling drug in the world, Keytruda, behind AbbVie's (NYSE: ABBV) immunology drug, Humira. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie, Amgen, Bristol Myers Squibb, Johnson & Johnson, and Merck & Co. With 17 approved indicat... |
23,860 | 2021-10-18 00:00:00 UTC | Why Revance Therapeutics Stock Is Getting Crushed Today | ABBV | https://www.nasdaq.com/articles/why-revance-therapeutics-stock-is-getting-crushed-today-2021-10-18 | null | null | What happened
Shares of the aesthetic and therapeutic company Revance Therapeutics (NASDAQ: RVNC) are in for a turbulent Monday. In premarket trading, the biopharma's shares sank by as much as 34% on heavy volume.
What's sparking this double-digit sell-off? After the closing bell last Friday, Revance announced that the... | So what DaxibotulinumtoxinA for Injection was expected to compete against AbbVie's blockbuster cosmetic therapy Botox, which the biotech acquired when it merged with Allergan last year. So, if things go smoothly, Revance could have this rival to AbbVie's Botox on the market by mid to late 2022. After the closing bell l... | So what DaxibotulinumtoxinA for Injection was expected to compete against AbbVie's blockbuster cosmetic therapy Botox, which the biotech acquired when it merged with Allergan last year. So, if things go smoothly, Revance could have this rival to AbbVie's Botox on the market by mid to late 2022. What happened Shares of ... | So what DaxibotulinumtoxinA for Injection was expected to compete against AbbVie's blockbuster cosmetic therapy Botox, which the biotech acquired when it merged with Allergan last year. So, if things go smoothly, Revance could have this rival to AbbVie's Botox on the market by mid to late 2022. After the closing bell l... | So what DaxibotulinumtoxinA for Injection was expected to compete against AbbVie's blockbuster cosmetic therapy Botox, which the biotech acquired when it merged with Allergan last year. So, if things go smoothly, Revance could have this rival to AbbVie's Botox on the market by mid to late 2022. The silver lining, if yo... |
23,861 | 2021-10-18 00:00:00 UTC | 3 High-Yield Dividend Stocks I'm Not Selling Anytime Soon | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-im-not-selling-anytime-soon-2021-10-18 | null | null | I like the noun version of "yield" a lot more than I like the verb. One means making money. The other means giving up.
Admittedly, I don't have many stocks in my portfolio that pay high dividend yields. My positions tend to focus more on growth than on dividends. However, I do own a few high-yield dividend stocks. Here... | AbbVie recently announced that it's partnering with Regenxbio to gain rights to a late-stage gene therapy targeting wet age-related macular degeneration. AbbVie AbbVie (NYSE: ABBV) is only one dividend increase away from becoming a Dividend King -- S&P 500 members with at least 50 consecutive years of dividend increase... | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Keith Speights owns shares of AbbVie, Devon Energy, and Enterprise Products Partners. AbbVie AbbVie (NYSE: ABBV) is only one dividend increase away from becoming a Dividend King -- S&P 500 members with at least 50 consecutive years of dividend increases.... | AbbVie AbbVie (NYSE: ABBV) is only one dividend increase away from becoming a Dividend King -- S&P 500 members with at least 50 consecutive years of dividend increases. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Keith Speights owns shares of AbbVie, Devon Energy, and Enterprise Products Partners.... | AbbVie AbbVie (NYSE: ABBV) is only one dividend increase away from becoming a Dividend King -- S&P 500 members with at least 50 consecutive years of dividend increases. That's especially encouraging considering that AbbVie's dividend yield already stands at nearly 4.8%. Let's address the elephant in the room with AbbVi... |
23,862 | 2021-10-18 00:00:00 UTC | 7 Blue Chips to Shield Your Portfolio From Market Downturn | ABBV | https://www.nasdaq.com/articles/7-blue-chips-to-shield-your-portfolio-from-market-downturn-2021-10-18 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors fearful of a stock market correction currently playing out for October should accumulate blue-chip stocks. The market downturn is long overdue. October may have seasonal weakness, thanks to epic crashes like the one in 1929. In 1987, the crash occ... | They are: AbbVie (NYSE:ABBV) Consolidated Edison (NYSE:ED) Coca-Cola (NYSE:KO) PepsiCo (NASDAQ:PEP) Procter & Gamble (NYSE:PG) Raytheon Technologies (NYSE:RTX) Unilever (NYSE:UL) Chart courtesy of Stock Rover All but Unilever score well on growth. Blue-Chip Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock... | They are: AbbVie (NYSE:ABBV) Consolidated Edison (NYSE:ED) Coca-Cola (NYSE:KO) PepsiCo (NASDAQ:PEP) Procter & Gamble (NYSE:PG) Raytheon Technologies (NYSE:RTX) Unilever (NYSE:UL) Chart courtesy of Stock Rover All but Unilever score well on growth. Blue-Chip Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock... | They are: AbbVie (NYSE:ABBV) Consolidated Edison (NYSE:ED) Coca-Cola (NYSE:KO) PepsiCo (NASDAQ:PEP) Procter & Gamble (NYSE:PG) Raytheon Technologies (NYSE:RTX) Unilever (NYSE:UL) Chart courtesy of Stock Rover All but Unilever score well on growth. Blue-Chip Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock... | They are: AbbVie (NYSE:ABBV) Consolidated Edison (NYSE:ED) Coca-Cola (NYSE:KO) PepsiCo (NASDAQ:PEP) Procter & Gamble (NYSE:PG) Raytheon Technologies (NYSE:RTX) Unilever (NYSE:UL) Chart courtesy of Stock Rover All but Unilever score well on growth. Blue-Chip Stocks to Buy: AbbVie (ABBV) Source: Piotr Swat / Shutterstock... |
23,863 | 2021-10-16 00:00:00 UTC | 2 Buffett Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/2-buffett-stocks-to-buy-and-hold-forever-2021-10-16 | null | null | It's an understatement to say Warren Buffett knows a thing or two about investing. Few if any CEOs have generated such high returns as consistently and for as long as Buffett has.
Although his total returns have actually lagged well behind the S&P 500 for the past decade, that's really a more recent phenomenon and a re... | But AbbVie says the market has it wrong because the FDA's decision is based on the agency's study of Xeljanz, made by Pfizer, which has a different safety profile than that of Rinvoq. AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) is a beaten-down Buffett stock that has dragged the portfolio lower. AbbVie was clobbere... | AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) is a beaten-down Buffett stock that has dragged the portfolio lower. AbbVie was clobbered because its arthritis therapy Rinvoq is a JAK-inhibiting prescription drug that is supposed to replace Humira when it goes off-patent. Humira, of course, has been AbbVie's money-make... | Despite this muscular effort, Amazon's stock is down 14% from the highs it hit this summer, and while it might not be as discounted as AbbVie, its stock is one that belongs in the long-term holding folder of your portfolio. AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) is a beaten-down Buffett stock that has dragged ... | AbbVie Pharmaceutical giant AbbVie (NYSE: ABBV) is a beaten-down Buffett stock that has dragged the portfolio lower. AbbVie was clobbered because its arthritis therapy Rinvoq is a JAK-inhibiting prescription drug that is supposed to replace Humira when it goes off-patent. Humira, of course, has been AbbVie's money-make... |
23,864 | 2021-10-15 00:00:00 UTC | U.S. FDA declines to approve Revance's frown-line treatment | ABBV | https://www.nasdaq.com/articles/u.s.-fda-declines-to-approve-revances-frown-line-treatment-2021-10-15 | null | null | Adds background, CEO comment, share move
Oct 15 (Reuters) - Revance Therapeutics Inc RVNC.O said on Friday the U.S. Food and Drug Administration had declined to approve its long-actinginjectable drug to treat moderate to severe frown lines, sending its shares plunging 29%.
The company said the FDA pointed to "deficienc... | Revance's DaxibotulinumtoxinA for Injection, a potential rival for AbbVie Inc's ABBV.N Botox anti-wrinkle injection, was successful in reducing moderate to severe frown lines in a late-stage study in December 2018. Adds background, CEO comment, share move Oct 15 (Reuters) - Revance Therapeutics Inc RVNC.O said on Frida... | Revance's DaxibotulinumtoxinA for Injection, a potential rival for AbbVie Inc's ABBV.N Botox anti-wrinkle injection, was successful in reducing moderate to severe frown lines in a late-stage study in December 2018. Adds background, CEO comment, share move Oct 15 (Reuters) - Revance Therapeutics Inc RVNC.O said on Frida... | Revance's DaxibotulinumtoxinA for Injection, a potential rival for AbbVie Inc's ABBV.N Botox anti-wrinkle injection, was successful in reducing moderate to severe frown lines in a late-stage study in December 2018. Adds background, CEO comment, share move Oct 15 (Reuters) - Revance Therapeutics Inc RVNC.O said on Frida... | Revance's DaxibotulinumtoxinA for Injection, a potential rival for AbbVie Inc's ABBV.N Botox anti-wrinkle injection, was successful in reducing moderate to severe frown lines in a late-stage study in December 2018. Adds background, CEO comment, share move Oct 15 (Reuters) - Revance Therapeutics Inc RVNC.O said on Frida... |
23,865 | 2021-10-15 00:00:00 UTC | AbbVie's Risankizumab Gets CHMP Positive Opinion For Active Psoriatic Arthritis Treatment | ABBV | https://www.nasdaq.com/articles/abbvies-risankizumab-gets-chmp-positive-opinion-for-active-psoriatic-arthritis-treatment | null | null | (RTTNews) - AbbVie (ABBV) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP recommended the approval of Risankizumab (SKYRIZI) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate respo... | (RTTNews) - AbbVie (ABBV) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP recommended the approval of Risankizumab (SKYRIZI) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate respo... | (RTTNews) - AbbVie (ABBV) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP recommended the approval of Risankizumab (SKYRIZI) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate respo... | (RTTNews) - AbbVie (ABBV) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP recommended the approval of Risankizumab (SKYRIZI) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate respo... | (RTTNews) - AbbVie (ABBV) said that the European Medicines Agency's or EMA Committee for Medicinal Products for Human Use or CHMP recommended the approval of Risankizumab (SKYRIZI) alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults who have had an inadequate respo... |
23,866 | 2021-10-15 00:00:00 UTC | Want More Monthly Income? Invest in These 3 Stocks | ABBV | https://www.nasdaq.com/articles/want-more-monthly-income-invest-in-these-3-stocks-2021-10-15 | null | null | Whether you're a retiree looking to help pay your bills or you just want to save up for your next vacation, everyone can use some extra cash every month. And one way you can generate more money for your portfolio is by investing in dividend stocks. Few dividend stocks pay on a monthly basis, but you can still collect c... | AbbVie anticipates that its adjusted per-share earnings will top more than $12 this year, strong enough to support its current payout, which totals just $5.20 per share on an annual basis. Below, I'll show you how investing just over $22,000 across three stocks -- AbbVie (NYSE: ABBV), Enbridge (NYSE: ENB), and BCE (NYS... | Below, I'll show you how investing just over $22,000 across three stocks -- AbbVie (NYSE: ABBV), Enbridge (NYSE: ENB), and BCE (NYSE: BCE) -- can generate at least $100 in cash for your portfolio every month. AbbVie Biopharmaceutical company AbbVie is a big name in the healthcare industry with revenue topping more than... | Below, I'll show you how investing just over $22,000 across three stocks -- AbbVie (NYSE: ABBV), Enbridge (NYSE: ENB), and BCE (NYSE: BCE) -- can generate at least $100 in cash for your portfolio every month. AbbVie Biopharmaceutical company AbbVie is a big name in the healthcare industry with revenue topping more than... | Below, I'll show you how investing just over $22,000 across three stocks -- AbbVie (NYSE: ABBV), Enbridge (NYSE: ENB), and BCE (NYSE: BCE) -- can generate at least $100 in cash for your portfolio every month. AbbVie Biopharmaceutical company AbbVie is a big name in the healthcare industry with revenue topping more than... |
23,867 | 2021-10-13 00:00:00 UTC | AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 14, 2021 | ABBV | https://www.nasdaq.com/articles/abbvie-inc.-abbv-ex-dividend-date-scheduled-for-october-14-2021-2021-10-13 | null | null | AbbVie Inc. (ABBV) will begin trading ex-dividend on October 14, 2021. A cash dividend payment of $1.3 per share is scheduled to be paid on November 15, 2021. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABBV has paid the same ... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABBV's forecasted earnings growth in 2021 as 19.79%, compared to an industry average of 3.6%. For more information on the declaration, record and payment dates, visit the abbv Divi... | ABBV's current earnings per share, an indicator of a company's profitability, is $3.71. The following ETF(s) have ABBV as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF (FTXH) First Trust Morningstar ETF (FDL) Invesco Dynamic Pharmaceuticals ETF (PJP) iShares Evolved U.S. AbbVie Inc. (ABBV) will begin trading... | Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the abbv Dividend History page. The following ETF(s) have ABBV as a top-10 holding: First Trust Nasdaq Pharmaceuticals ETF (FTXH) First Trust... | ABBV's current earnings per share, an indicator of a company's profitability, is $3.71. AbbVie Inc. (ABBV) will begin trading ex-dividend on October 14, 2021. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. |
23,868 | 2021-10-12 00:00:00 UTC | IVW, QCOM, ABBV, DHR: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ivw-qcom-abbv-dhr%3A-large-inflows-detected-at-etf-2021-10-12 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $275.8 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 474,050,000 to... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is off about 1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is off about 1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is off about 1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of IVW, in trading today Qualcomm Inc (Symbol: QCOM) is off about 1%, AbbVie Inc (Symbol: ABBV) is down about 0.9%, and Danaher Corp (Symbol: DHR) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
23,869 | 2021-10-12 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, BlackRock Health Sciences Trust II and Pennymac Mortgage Investment Trust | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-blackrock-health-sciences-trust-ii-and-pennymac-mortgage | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, AbbVie Inc (Symbol: ABBV), BlackRock Health Sciences Trust II (Symbol: BMEZ), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend o... | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, AbbVie Inc (Symbol: ABBV), BlackRock Health Sciences Trust II (Symbol: BMEZ), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABBV's recent stock price... | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, AbbVie Inc (Symbol: ABBV), BlackRock Health Sciences Trust II (Symbol: BMEZ), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend o... | Looking at the universe of stocks we cover at Dividend Channel, on 10/14/21, AbbVie Inc (Symbol: ABBV), BlackRock Health Sciences Trust II (Symbol: BMEZ), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend o... | As a percentage of ABBV's recent stock price of $109.94, this dividend works out to approximately 1.18%, so look for shares of AbbVie Inc to trade 1.18% lower — all else being equal — when ABBV shares open for trading on 10/14/21. AbbVie Inc (Symbol: ABBV): BlackRock Health Sciences Trust II (Symbol: BMEZ): Pennymac Mo... |
23,870 | 2021-10-11 00:00:00 UTC | Surprising Analyst 12-Month Target For XLG | ABBV | https://www.nasdaq.com/articles/surprising-analyst-12-month-target-for-xlg-2021-10-11 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P 500— Top 50 ETF (Sy... | Below is a twelve month price history chart comparing the stock performance of AMZN, MDT, and ABBV: Combined, AMZN, MDT, and ABBV represent 8.93% of the Invesco S&P 500— Top 50 ETF. Invesco S&P 500— Top 50 ETF XLG $337.35 $378.76 12.27% Amazon.com Inc AMZN $3288.62 $4167.26 26.72% Medtronic PLC MDT $125.27 $148.41 18.4... | Three of XLG's underlying holdings with notable upside to their analyst target prices are Amazon.com Inc (Symbol: AMZN), Medtronic PLC (Symbol: MDT), and AbbVie Inc (Symbol: ABBV). Similarly, MDT has 18.47% upside from the recent share price of $125.27 if the average analyst target price of $148.41/share is reached, an... | Similarly, MDT has 18.47% upside from the recent share price of $125.27 if the average analyst target price of $148.41/share is reached, and analysts on average are expecting ABBV to reach a target price of $127.64/share, which is 14.80% above the recent price of $111.18. Three of XLG's underlying holdings with notable... | Below is a twelve month price history chart comparing the stock performance of AMZN, MDT, and ABBV: Combined, AMZN, MDT, and ABBV represent 8.93% of the Invesco S&P 500— Top 50 ETF. Three of XLG's underlying holdings with notable upside to their analyst target prices are Amazon.com Inc (Symbol: AMZN), Medtronic PLC (Sy... |
23,871 | 2021-10-09 00:00:00 UTC | Is It Worth Considering AbbVie Inc. (NYSE:ABBV) For Its Upcoming Dividend? | ABBV | https://www.nasdaq.com/articles/is-it-worth-considering-abbvie-inc.-nyse%3Aabbv-for-its-upcoming-dividend-2021-10-09 | null | null | AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend. It is important to be aware of the ex-dividend date because any trade o... | Calculating the last year's worth of payments shows that AbbVie has a trailing yield of 4.7% on the current share price of $111.18. AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in 4 days. Meaning, you will need to purchase AbbVie's shares before the 14th of October to receive the dividend, which will be ... | NYSE:ABBV Historic Dividend October 9th 2021 Have Earnings And Dividends Been Growing? AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in 4 days. Meaning, you will need to purchase AbbVie's shares before the 14th of October to receive the dividend, which will be paid on the 15th of November. | AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in 4 days. Meaning, you will need to purchase AbbVie's shares before the 14th of October to receive the dividend, which will be paid on the 15th of November. Calculating the last year's worth of payments shows that AbbVie has a trailing yield of 4.7% on the cu... | AbbVie has been steadily growing its earnings per share, and it is paying out just 45% of its cash flow but an uncomfortably high 136% of its income. AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in 4 days. Meaning, you will need to purchase AbbVie's shares before the 14th of October to receive the divide... |
23,872 | 2021-10-07 00:00:00 UTC | Why AbbVie Stock Sank in September | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-sank-in-september-2021-10-07 | null | null | What happened
Shares of the Illinois-based AbbVie (NYSE: ABBV) sank by an eye-catching 10.7% last month, according to data provided by S&P Global Market Intelligence. That's equivalent to a $20 billion drop in market capitalization. What caused investors to hit the panic button on the drugmaker's stock last month? Earl... | AbbVie's next-generation rheumatoid arthritis med, Rinvoq, received a similar warning from the FDA because it belongs to the same class of medications as Pfizer's drug. What happened Shares of the Illinois-based AbbVie (NYSE: ABBV) sank by an eye-catching 10.7% last month, according to data provided by S&P Global Marke... | What happened Shares of the Illinois-based AbbVie (NYSE: ABBV) sank by an eye-catching 10.7% last month, according to data provided by S&P Global Market Intelligence. AbbVie's next-generation rheumatoid arthritis med, Rinvoq, received a similar warning from the FDA because it belongs to the same class of medications as... | Now what Is AbbVie's stock a bad news buy? 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. What happened Shares of the Illinois-based AbbVie (NYSE: ABBV) sank by an eye-catching 10.7% last month, according to data provided by S&P Global Market Intelligence... | AbbVie's next-generation rheumatoid arthritis med, Rinvoq, received a similar warning from the FDA because it belongs to the same class of medications as Pfizer's drug. Now what Is AbbVie's stock a bad news buy? * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie ... |
23,873 | 2021-10-07 00:00:00 UTC | ABBV Crosses Above Key Moving Average Level | ABBV | https://www.nasdaq.com/articles/abbv-crosses-above-key-moving-average-level-2021-10-07 | null | null | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.02, changing hands as high as $111.12 per share. AbbVie Inc shares are currently trading up about 1.3% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.02, changing hands as high as $111.12 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.02, changing hands as high as $111.12 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.02, changing hands as high as $111.12 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ra... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $111.02, changing hands as high as $111.12 per share. AbbVie Inc shares are currently trading up about 1.3% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... |
23,874 | 2021-10-07 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-2021-10-07 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Cardinal Health, Inc. (Symbol: CAH) $48.66 $58.78 20.79% AbbVie Inc (Symbol: ABBV) $109.32 $127.64 16.75% RenaissanceRe Holdings Ltd. (Symbol: RNR) $143.96 $166.75 15.83% Cincinnati Financial Corp. (Symbol: CINF) $116.47 $132.75 13.98% General Dynamics Corp (Symbol: GD) $199.36 $223.33 12.02% The average 12-month analy... | Cardinal Health, Inc. (Symbol: CAH) $48.66 $58.78 20.79% AbbVie Inc (Symbol: ABBV) $109.32 $127.64 16.75% RenaissanceRe Holdings Ltd. (Symbol: RNR) $143.96 $166.75 15.83% Cincinnati Financial Corp. (Symbol: CINF) $116.47 $132.75 13.98% General Dynamics Corp (Symbol: GD) $199.36 $223.33 12.02% The average 12-month analy... | Cardinal Health, Inc. (Symbol: CAH) $48.66 $58.78 20.79% AbbVie Inc (Symbol: ABBV) $109.32 $127.64 16.75% RenaissanceRe Holdings Ltd. (Symbol: RNR) $143.96 $166.75 15.83% Cincinnati Financial Corp. (Symbol: CINF) $116.47 $132.75 13.98% General Dynamics Corp (Symbol: GD) $199.36 $223.33 12.02% The average 12-month analy... | Cardinal Health, Inc. (Symbol: CAH) $48.66 $58.78 20.79% AbbVie Inc (Symbol: ABBV) $109.32 $127.64 16.75% RenaissanceRe Holdings Ltd. (Symbol: RNR) $143.96 $166.75 15.83% Cincinnati Financial Corp. (Symbol: CINF) $116.47 $132.75 13.98% General Dynamics Corp (Symbol: GD) $199.36 $223.33 12.02% The average 12-month analy... |
23,875 | 2021-10-07 00:00:00 UTC | Notable Thursday Option Activity: PLUG, ABBV, IDT | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-plug-abbv-idt-2021-10-07 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Plug Power Inc (Symbol: PLUG), where a total volume of 73,504 contracts has been traded thus far today, a contract volume which is representative of approximately 7.4 million underlying shares (given th... | Particularly high volume was seen for the $109 strike call option expiring October 15, 2021, with 4,179 contracts trading so far today, representing approximately 417,900 underlying shares of ABBV. Below is a chart showing PLUG's trailing twelve month trading history, with the $27 strike highlighted in orange: AbbVie I... | Below is a chart showing PLUG's trailing twelve month trading history, with the $27 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 33,171 contracts thus far today. Below is a chart showing ABBV's trailing twelve month trading history, with the $109 strike highlighted in orange: ... | Below is a chart showing ABBV's trailing twelve month trading history, with the $109 strike highlighted in orange: And IDT Corp (Symbol: IDT) saw options trading volume of 754 contracts, representing approximately 75,400 underlying shares or approximately 44.5% of IDT's average daily trading volume over the past month,... | Particularly high volume was seen for the $109 strike call option expiring October 15, 2021, with 4,179 contracts trading so far today, representing approximately 417,900 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $109 strike highlighted in orange: And IDT... |
23,876 | 2021-10-07 00:00:00 UTC | AbbVie: RINVOQ Meets Primary Endpoints In Phase 3 Studies - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie%3A-rinvoq-meets-primary-endpoints-in-phase-3-studies-quick-facts-2021-10-07 | null | null | (RTTNews) - AbbVie (ABBV) reported positive top-line results from the first of two studies of the phase 3 SELECT-AXIS 2 clinical trial evaluating RINVOQ in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy. RINVOQ met its primary endpoint of ASAS 40 response and all ra... | (RTTNews) - AbbVie (ABBV) reported positive top-line results from the first of two studies of the phase 3 SELECT-AXIS 2 clinical trial evaluating RINVOQ in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy. Separately, AbbVie reported positive top-line results from stu... | Separately, AbbVie reported positive top-line results from study 2 of the phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis, showing RINVOQ met the primary endpoint of Assessment in ASAS 40 response and the majority of ranked secondary endpoints at week 14. (RTTNews) - ... | (RTTNews) - AbbVie (ABBV) reported positive top-line results from the first of two studies of the phase 3 SELECT-AXIS 2 clinical trial evaluating RINVOQ in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy. Separately, AbbVie reported positive top-line results from stu... | Separately, AbbVie reported positive top-line results from study 2 of the phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis, showing RINVOQ met the primary endpoint of Assessment in ASAS 40 response and the majority of ranked secondary endpoints at week 14. (RTTNews) - ... |
23,877 | 2021-10-05 00:00:00 UTC | S&P 500 Analyst Moves: ABBV | ABBV | https://www.nasdaq.com/articles/sp-500-analyst-moves%3A-abbv-2021-10-05 | null | null | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #92 analyst pick, moving up by 40 spots.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those av... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #92 analyst pick, moving up by 40 spots. Looking at the stock price movement year to date, AbbVie is showing a gain of 2.8%. VIDEO: S&P 500 Analyst Moves: ABBV The views and opini... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #92 analyst pick, moving up by 40 spots. VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #92 analyst pick, moving up by 40 spots. VIDEO: S&P 500 Analyst Moves: ABBV The views and opinions expressed herein are the views and opinions of the author and do not necessarily... | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, AbbVie is now the #92 analyst pick, moving up by 40 spots. Looking at the stock price movement year to date, AbbVie is showing a gain of 2.8%. VIDEO: S&P 500 Analyst Moves: ABBV The views and opini... |
23,878 | 2021-10-05 00:00:00 UTC | With Acceleron Acquisition Merck Stock Is Likely To See A Multiple Revision | ABBV | https://www.nasdaq.com/articles/with-acceleron-acquisition-merck-stock-is-likely-to-see-a-multiple-revision-2021-10-05 | null | null | [Updated: Oct 1, 2021] Merck To Acquire Acceleron
Merck (NYSE: MRK) yesterday announced that it will acquire Acceleron Pharma – a biopharmaceutical company focused on rare diseases – for $11.5 billion funded in cash and debt. Acceleron has multiple potentially blockbuster drugs in its pipeline. To name a few, Sotaterce... | Another drug – Reblozyl (in partnership with Bristol Myers Squibb) – which is used to treat anemia in myelodysplastic syndromes (MDS) – is estimated to garner over $2 billion in peak sales. Merck’s cash-cow – Keytruda – continues to gain share in several markets given its approval in multiple indications, including, lu... | [Updated: Sep 21, 2021] Merck Stock Undervalued The stock price of Merck (NYSE: MRK) reached its 52-week high of around $82 in Sep 2020. The revenue growth can largely be attributed to market share gains for its mega-blockbuster drug – Keytruda – approved for multiple types of cancer treatments. Despite a large EPS gro... | [Updated: Sep 21, 2021] Merck Stock Undervalued The stock price of Merck (NYSE: MRK) reached its 52-week high of around $82 in Sep 2020. Despite a large EPS growth over the recent years, Merck’s P/E multiple has contracted 49% to 33x currently, compared to levels of 64x seen in 2017, and we believe that the multiple wi... | We continue to believe that MRK stock is undervalued, and going by our Merck valuation of $91 a share, based on our adjusted EPS forecast of $5.65 and a P/E multiple of around 16x for 2021, there is more than 20% upside likely from the current levels of around $75. MRK stock is down more than 15% over the last year or ... |
23,879 | 2021-10-05 00:00:00 UTC | Here's Why Merck Stock May Continue To Rise | ABBV | https://www.nasdaq.com/articles/heres-why-merck-stock-may-continue-to-rise-2021-10-05 | null | null | [Updated: Oct 4, 2021] Merck Stock Rise
The stock price of Merck (NYSE: MRK) surged 8% to levels of $81 on Friday, Oct 1, after the company announced that its Molnupiravir pill reduces the risk of hospitalization and death by 50% for patients with mild to moderate Covid-19. The data is so encouraging that Merck has now... | Answer: If you buy and hold Merck stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you – at least if the company is otherwise strong. Another drug – Reblozyl (in partnership with Bristol Myers Squibb) – which is used to treat anemia in myelodysp... | [Updated: Oct 4, 2021] Merck Stock Rise The stock price of Merck (NYSE: MRK) surged 8% to levels of $81 on Friday, Oct 1, after the company announced that its Molnupiravir pill reduces the risk of hospitalization and death by 50% for patients with mild to moderate Covid-19. According to the Trefis Machine Learning Engi... | According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for MRK stock average around 4% in the next one-month (twenty-one trading days) period after experiencing a 11% rise over the previous week (five trading days) implying that ... | For additional details about Merck historical returns, and return comparison to peers see Merck (MRK) Stock Return Merck Stock Movements: Q&A with Trefis AI Engine Q1: Is the price forecast for Merck stock higher after a drop? MRK stock is down more than 15% over the last year or so, despite revenue increasing 6% over ... |
23,880 | 2021-10-04 00:00:00 UTC | Investing in Pharma Stocks? Watch for These 2 Red Flags | ABBV | https://www.nasdaq.com/articles/investing-in-pharma-stocks-watch-for-these-2-red-flags-2021-10-04 | null | null | Pharmaceutical companies can be a great pickup for the conservative portion of your portfolio. Everyone is going to need the life-saving medications that pharmas develop at one point or another, and that means they're never going to go out of style.
Still, it takes more than making medicines for a drug stock to be lucr... | Take AbbVie (NYSE: ABBV), for example. In short, not all pharma companies have enough in their pipeline to pull off such a smooth transition between revenue-bearing programs like AbbVie is planning. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. | Take AbbVie (NYSE: ABBV), for example. In short, not all pharma companies have enough in their pipeline to pull off such a smooth transition between revenue-bearing programs like AbbVie is planning. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. | Take AbbVie (NYSE: ABBV), for example. In short, not all pharma companies have enough in their pipeline to pull off such a smooth transition between revenue-bearing programs like AbbVie is planning. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. | * They just revealed what they believe are the ten best stocks for investors to buy right now… and AbbVie wasn't one of them! Take AbbVie (NYSE: ABBV), for example. In short, not all pharma companies have enough in their pipeline to pull off such a smooth transition between revenue-bearing programs like AbbVie is plann... |
23,881 | 2021-10-03 00:00:00 UTC | Johnson & Johnson Sell-Off: Is It a Buying Opportunity? | ABBV | https://www.nasdaq.com/articles/johnson-johnson-sell-off%3A-is-it-a-buying-opportunity-2021-10-03 | null | null | With the S&P 500 just 4% off of its all-time high, investors looking for safe and growing income are having to look much more closely than they did five or 10 years ago. Fortunately, there are still viable options for investors seeking income with reduced volatility.
Stocks that have raised their dividends for at least... | Johnson & Johnson and AbbVie's (NYSE: ABBV) blockbuster oncology drug Imbruvica was first approved by the FDA in 2013 and won't likely face any competition from generic drugs until at least early next decade. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie and Johnson... | Johnson & Johnson and AbbVie's (NYSE: ABBV) blockbuster oncology drug Imbruvica was first approved by the FDA in 2013 and won't likely face any competition from generic drugs until at least early next decade. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie and Johnson... | Johnson & Johnson and AbbVie's (NYSE: ABBV) blockbuster oncology drug Imbruvica was first approved by the FDA in 2013 and won't likely face any competition from generic drugs until at least early next decade. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie and Johnson... | Johnson & Johnson and AbbVie's (NYSE: ABBV) blockbuster oncology drug Imbruvica was first approved by the FDA in 2013 and won't likely face any competition from generic drugs until at least early next decade. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Kody Kester owns shares of AbbVie and Johnson... |
23,882 | 2021-10-02 00:00:00 UTC | Here's What Warren Buffett Looks For With Healthcare Stocks | ABBV | https://www.nasdaq.com/articles/heres-what-warren-buffett-looks-for-with-healthcare-stocks-2021-10-02 | null | null | If you're stumped about how to find lucrative healthcare stocks, Warren Buffett might be able to help. As the value investing rockstar of the late 20th century, Buffett's patient and conservative approach should be a tool in every investor's collection.
Today, I'll be explaining the most relevant bits of Buffett's phil... | Of the healthcare stocks he owns, he seems to prefer drug developers like AbbVie and Biogen over hardware companies like Intuitive and Retractable. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Alex Carchidi owns shares of AbbVie. The da Vinci brand of surgical robots has widespread and positive rec... | Of the healthcare stocks he owns, he seems to prefer drug developers like AbbVie and Biogen over hardware companies like Intuitive and Retractable. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Alex Carchidi owns shares of AbbVie. For a company like Intuitive Surgical, (NASDAQ: ISRG) which makes rob... | Of the healthcare stocks he owns, he seems to prefer drug developers like AbbVie and Biogen over hardware companies like Intuitive and Retractable. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Alex Carchidi owns shares of AbbVie. Nonetheless, I think that both Retractable Technologies and Intuitive... | Of the healthcare stocks he owns, he seems to prefer drug developers like AbbVie and Biogen over hardware companies like Intuitive and Retractable. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Alex Carchidi owns shares of AbbVie. Once a hospital purchases one of Intuitive's da Vinci surgical robots... |
23,883 | 2021-10-01 00:00:00 UTC | Noteworthy ETF Outflows: XLV, ABBV, LLY, BMY | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-xlv-abbv-lly-bmy-2021-10-01 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $509.1 million dollar outflow -- that's a 1.6% decrease week over week (from 247,370,000 to 243,3... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.5%, Eli Lilly (Symbol: LLY) is off about 2.2%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.5%, Eli Lilly (Symbol: LLY) is off about 2.2%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 0.2%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year pr... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.5%, Eli Lilly (Symbol: LLY) is off about 2.2%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.5%, Eli Lilly (Symbol: LLY) is off about 2.2%, and Bristol Myers Squibb Co. (Symbol: BMY) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF... |
23,884 | 2021-09-30 00:00:00 UTC | California judge questions counties' opioid case against drugmakers at trial's end | ABBV | https://www.nasdaq.com/articles/california-judge-questions-counties-opioid-case-against-drugmakers-at-trials-end-2021-09 | null | null | By Nate Raymond
Sept 30 (Reuters) - A California judge on Thursday said several large counties accusing four drugmakers of fueling an opioid epidemic had presented a "dearth of evidence" during a multi-billion dollar trial to support finding the companies' pain pill marketing caused the health crisis.
Judge Peter Wilso... | Judge Peter Wilson sharply questioned the counties' lawyer during closing arguments about what evidence would support finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit liable for the epidemic. By Nate Raymond Sept 30 (Reuters... | Judge Peter Wilson sharply questioned the counties' lawyer during closing arguments about what evidence would support finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit liable for the epidemic. By Nate Raymond Sept 30 (Reuters... | Judge Peter Wilson sharply questioned the counties' lawyer during closing arguments about what evidence would support finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit liable for the epidemic. By Nate Raymond Sept 30 (Reuters... | Judge Peter Wilson sharply questioned the counties' lawyer during closing arguments about what evidence would support finding Johnson & Johnson JNJ.N, Teva Pharmaceutical Industries Ltd TEVA.TA, Endo International PLC ENDP.O and AbbVie Inc's ABBV.N Allergan unit liable for the epidemic. By Nate Raymond Sept 30 (Reuters... |
23,885 | 2021-09-30 00:00:00 UTC | Interesting ABBV Put And Call Options For November 12th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-november-12th-2021-09-30 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the November 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 12th contracts and identified one put and one call contract of particular interest.
The put... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $107.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $2.57. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new November 12th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $110.00 strike highlighted in red: Consi... |
23,886 | 2021-09-30 00:00:00 UTC | AbbVie: New Analysis Show RINVOQ's Potential To Alleviate Itch And Rash In Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/abbvie%3A-new-analysis-show-rinvoqs-potential-to-alleviate-itch-and-rash-in-atopic | null | null | (RTTNews) - AbbVie (ABBV) reported new analyses from the phase 3 RINVOQ atopic dermatitis clinical trial program. The company said one analysis showed a greater proportion of patients treated with RINVOQ with or without topical corticosteroids achieved 75 percent improvement in the Eczema Area Severity Index at week 16... | "These data further highlight RINVOQ's potential to help alleviate the itch and rash in moderate to severe atopic dermatitis, offering additional support of its efficacy across various patient characteristics and areas of the body," said Thomas Hudson, chief scientific officer, AbbVie. (RTTNews) - AbbVie (ABBV) reporte... | "These data further highlight RINVOQ's potential to help alleviate the itch and rash in moderate to severe atopic dermatitis, offering additional support of its efficacy across various patient characteristics and areas of the body," said Thomas Hudson, chief scientific officer, AbbVie. (RTTNews) - AbbVie (ABBV) reporte... | "These data further highlight RINVOQ's potential to help alleviate the itch and rash in moderate to severe atopic dermatitis, offering additional support of its efficacy across various patient characteristics and areas of the body," said Thomas Hudson, chief scientific officer, AbbVie. (RTTNews) - AbbVie (ABBV) reporte... | (RTTNews) - AbbVie (ABBV) reported new analyses from the phase 3 RINVOQ atopic dermatitis clinical trial program. "These data further highlight RINVOQ's potential to help alleviate the itch and rash in moderate to severe atopic dermatitis, offering additional support of its efficacy across various patient characteristi... |
23,887 | 2021-09-29 00:00:00 UTC | Here's How a New Investor Started Her Portfolio With Just 10 Top Stocks | ABBV | https://www.nasdaq.com/articles/heres-how-a-new-investor-started-her-portfolio-with-just-10-top-stocks-2021-09-29 | null | null | Investing in the stock market to successfully generate portfolio returns doesn't require some super special set of skills or secret knowledge. It requires research, patience, and time. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributor Rachel Warren tells fellow Fool contributor Brian Withe... | It's like a couple of the healthcare stocks we talked about earlier, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). Rachel Warren owns shares of AbbVie and Johnson & Johnson. Investing in the stock market to successfully generate portfolio returns doesn't require some super special set of skills or secret knowl... | It's like a couple of the healthcare stocks we talked about earlier, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). Rachel Warren owns shares of AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributor Rachel Warren tells fellow Fool contributor Brian Withers... | It's like a couple of the healthcare stocks we talked about earlier, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). Rachel Warren owns shares of AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributor Rachel Warren tells fellow Fool contributor Brian Withers... | It's like a couple of the healthcare stocks we talked about earlier, Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV). Rachel Warren owns shares of AbbVie and Johnson & Johnson. * They just revealed what they believe are the ten best stocks for investors to buy right now... and Johnson & Johnson wasn't one of them... |
23,888 | 2021-09-29 00:00:00 UTC | Here's Why Investors Shouldn't Count Out Johnson & Johnson as a Coronavirus Vaccine Stock | ABBV | https://www.nasdaq.com/articles/heres-why-investors-shouldnt-count-out-johnson-johnson-as-a-coronavirus-vaccine-stock-2021 | null | null | In the early days of the coronavirus vaccine race, it seemed as if Johnson & Johnson (NYSE: JNJ) was neck-and-neck with other major contenders. A range of factors including manufacturing delays and quality control issues caused the company to fall behind in the race, and despite the proven efficacy of its vaccine and t... | Brian Withers: Yes, I look at both AbbVie and J&J, and they have similar aspects. Rachel Warren owns shares of AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Rachel Warren, Toby Bordelon, and Brian Withers discuss why investors shouldn't dismiss Johnson & ... | Brian Withers: Yes, I look at both AbbVie and J&J, and they have similar aspects. Rachel Warren owns shares of AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Rachel Warren, Toby Bordelon, and Brian Withers discuss why investors shouldn't dismiss Johnson & ... | Brian Withers: Yes, I look at both AbbVie and J&J, and they have similar aspects. Rachel Warren owns shares of AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Rachel Warren, Toby Bordelon, and Brian Withers discuss why investors shouldn't dismiss Johnson & ... | Brian Withers: Yes, I look at both AbbVie and J&J, and they have similar aspects. Rachel Warren owns shares of AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Rachel Warren, Toby Bordelon, and Brian Withers discuss why investors shouldn't dismiss Johnson & ... |
23,889 | 2021-09-29 00:00:00 UTC | Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors | ABBV | https://www.nasdaq.com/articles/heres-why-abbvie-is-a-great-healthcare-stock-for-long-term-investors-2021-09-29 | null | null | Pharmaceutical giant AbbVie (NYSE: ABBV) is best known for its mega-blockbuster drug Humira, which raked in more revenue than any other medicine in the world in yet another year of successive growth in 2020. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Brian Withers and Rachel Warren... | Pharmaceutical giant AbbVie (NYSE: ABBV) is best known for its mega-blockbuster drug Humira, which raked in more revenue than any other medicine in the world in yet another year of successive growth in 2020. In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Brian Withers and Rachel Warren... | In this segment of Backstage Pass, recorded on Sept. 20, 2021, Fool contributors Brian Withers and Rachel Warren discuss what makes AbbVie such a stalwart choice for the long-term investor's portfolio. See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: The next company is AbbVie, I was jus... | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: The next company is AbbVie, I was just going to jump on to the next company, the next company is AbbVie. For those who don't know, AbbVie started out, it was a split off from Abbott, and Abbott has been just over a century-old company that... | See the 10 stocks *Stock Advisor returns as of September 17, 2021 Brian Withers: The next company is AbbVie, I was just going to jump on to the next company, the next company is AbbVie. But I would say that AbbVie's product portfolio, like you were mentioning has grown so much in recent years, and with its acquisition ... |
23,890 | 2021-09-28 00:00:00 UTC | FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine | ABBV | https://www.nasdaq.com/articles/fda-approves-abbvies-qulipta-for-preventive-treatment-of-migraine-2021-09-28 | null | null | (RTTNews) - The U.S. Food and Drug Administration approved AbbVie's (ABBV) Qulipta or atogepant for the preventive treatment of episodic migraine in adults.
Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migra... | (RTTNews) - The U.S. Food and Drug Administration approved AbbVie's (ABBV) Qulipta or atogepant for the preventive treatment of episodic migraine in adults. AbbVie noted that Qulipta demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults ... | AbbVie noted that Qulipta demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks 1-4. (RTTNews) - The U.S. Food and D... | AbbVie noted that Qulipta demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks 1-4. (RTTNews) - The U.S. Food and D... | AbbVie noted that Qulipta demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12-week treatment period with significant reductions seen in weeks 1-4. (RTTNews) - The U.S. Food and D... |
23,891 | 2021-09-28 00:00:00 UTC | U.S. FDA approves AbbVie's migraine prevention drug | ABBV | https://www.nasdaq.com/articles/u.s.-fda-approves-abbvies-migraine-prevention-drug-2021-09-28 | null | null | Sept 28 (Reuters) - AbbVie Inc ABBV.N said on Tuesday the U.S. health regulator approved its once-daily oral medicine for the preventive treatment of migraine in adults, adding a third drug to the drugmaker's bank of products for severe headaches.
The drugmaker acquired the medicine, Qulipta, as part of its $63 billion... | Sept 28 (Reuters) - AbbVie Inc ABBV.N said on Tuesday the U.S. health regulator approved its once-daily oral medicine for the preventive treatment of migraine in adults, adding a third drug to the drugmaker's bank of products for severe headaches. The drugmaker acquired the medicine, Qulipta, as part of its $63 billion... | Sept 28 (Reuters) - AbbVie Inc ABBV.N said on Tuesday the U.S. health regulator approved its once-daily oral medicine for the preventive treatment of migraine in adults, adding a third drug to the drugmaker's bank of products for severe headaches. The drugmaker acquired the medicine, Qulipta, as part of its $63 billion... | Sept 28 (Reuters) - AbbVie Inc ABBV.N said on Tuesday the U.S. health regulator approved its once-daily oral medicine for the preventive treatment of migraine in adults, adding a third drug to the drugmaker's bank of products for severe headaches. The drugmaker acquired the medicine, Qulipta, as part of its $63 billion... | Sept 28 (Reuters) - AbbVie Inc ABBV.N said on Tuesday the U.S. health regulator approved its once-daily oral medicine for the preventive treatment of migraine in adults, adding a third drug to the drugmaker's bank of products for severe headaches. The drugmaker acquired the medicine, Qulipta, as part of its $63 billion... |
23,892 | 2021-09-28 00:00:00 UTC | 7 Biotech Stocks Entering the Golden Boom Phase | ABBV | https://www.nasdaq.com/articles/7-biotech-stocks-entering-the-golden-boom-phase-2021-09-28 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Biotech stocks are infamously one of the most volatile sectors in the stock market. Investors often venture into speculative companies with no proven pipelines. Emerging firms with a pipeline of drugs and products still in the clinical phase post little to ... | AbbVie (NYSE:ABBV) Horizon Therapeutics (NASDAQ:HZNP) Johnson & Johnson (NYSE:JNJ) Eli Lilly (NYSE:LLY) Merck & Co (NYSE:MRK) Novartis (NYSE:NVS) Regeneron Pharmaceuticals (NASDAQ:REGN) Biotech Stocks About to Boom: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shu... | AbbVie (NYSE:ABBV) Horizon Therapeutics (NASDAQ:HZNP) Johnson & Johnson (NYSE:JNJ) Eli Lilly (NYSE:LLY) Merck & Co (NYSE:MRK) Novartis (NYSE:NVS) Regeneron Pharmaceuticals (NASDAQ:REGN) Biotech Stocks About to Boom: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shu... | AbbVie (NYSE:ABBV) Horizon Therapeutics (NASDAQ:HZNP) Johnson & Johnson (NYSE:JNJ) Eli Lilly (NYSE:LLY) Merck & Co (NYSE:MRK) Novartis (NYSE:NVS) Regeneron Pharmaceuticals (NASDAQ:REGN) Biotech Stocks About to Boom: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shu... | AbbVie (NYSE:ABBV) Horizon Therapeutics (NASDAQ:HZNP) Johnson & Johnson (NYSE:JNJ) Eli Lilly (NYSE:LLY) Merck & Co (NYSE:MRK) Novartis (NYSE:NVS) Regeneron Pharmaceuticals (NASDAQ:REGN) Biotech Stocks About to Boom: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shu... |
23,893 | 2021-09-28 00:00:00 UTC | 3 Top Stocks for Retirees | ABBV | https://www.nasdaq.com/articles/3-top-stocks-for-retirees-2021-09-28 | null | null | Let's face it. The average 35-year-old's investment portfolio should look considerably different than the average 65-year-old's. The former has plenty of time to ride out the market's inevitable ups and downs, and probably doesn't need investment income just yet. The latter, on the other hand, is likely in or nearing r... | AbbVie Investors who know anything about AbbVie (NYSE: ABBV) probably know it's the name behind arthritis and Crohn's disease treatment Humira, which accounts for nearly 40% of the company's revenue. Humira is AbbVie's breadwinner, but the drug is also going to start losing its most important patent protections beginni... | Procter & Gamble AbbVie's isn't the only low-risk, proven portfolio that future or current retirees can feel good about plugging into. AbbVie Investors who know anything about AbbVie (NYSE: ABBV) probably know it's the name behind arthritis and Crohn's disease treatment Humira, which accounts for nearly 40% of the comp... | AbbVie Investors who know anything about AbbVie (NYSE: ABBV) probably know it's the name behind arthritis and Crohn's disease treatment Humira, which accounts for nearly 40% of the company's revenue. Humira is AbbVie's breadwinner, but the drug is also going to start losing its most important patent protections beginni... | AbbVie Investors who know anything about AbbVie (NYSE: ABBV) probably know it's the name behind arthritis and Crohn's disease treatment Humira, which accounts for nearly 40% of the company's revenue. Humira is AbbVie's breadwinner, but the drug is also going to start losing its most important patent protections beginni... |
23,894 | 2021-09-28 00:00:00 UTC | FOCUS-COVID-19 pill developers aim to top Merck, Pfizer efforts | ABBV | https://www.nasdaq.com/articles/focus-covid-19-pill-developers-aim-to-top-merck-pfizer-efforts-2021-09-28 | null | null | By Deena Beasley
Sept 28 (Reuters) - As Merck & Co MRK.N and Pfizer Inc PFE.N prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.
Enanta Pharmaceuticals ENTA.O, Pardes Biosc... | Enanta, which gets most of its revenue from a hepatitis C deal with AbbVie Inc ABBV.N, scanned its library of antiviral compounds early in 2020. By Deena Beasley Sept 28 (Reuters) - As Merck & Co MRK.N and Pfizer Inc PFE.N prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are li... | Enanta, which gets most of its revenue from a hepatitis C deal with AbbVie Inc ABBV.N, scanned its library of antiviral compounds early in 2020. By Deena Beasley Sept 28 (Reuters) - As Merck & Co MRK.N and Pfizer Inc PFE.N prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are li... | Enanta, which gets most of its revenue from a hepatitis C deal with AbbVie Inc ABBV.N, scanned its library of antiviral compounds early in 2020. By Deena Beasley Sept 28 (Reuters) - As Merck & Co MRK.N and Pfizer Inc PFE.N prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are li... | Enanta, which gets most of its revenue from a hepatitis C deal with AbbVie Inc ABBV.N, scanned its library of antiviral compounds early in 2020. They also need to be given early to be most effective. The drug will be tested at once daily dosing with no ritonavir boosting, Luly said. |
23,895 | 2021-09-27 00:00:00 UTC | Could AbbVie's New Collaboration Be a Blockbuster? | ABBV | https://www.nasdaq.com/articles/could-abbvies-new-collaboration-be-a-blockbuster-2021-09-27 | null | null | Earlier this month, AbbVie (NYSE: ABBV) announced a deal with biotechnology company Regenxbio (NASDAQ: RGNX) to treat eye disorders using gene therapy. Specifically, the two companies are collaborating to develop and commercialize a gene therapy candidate, RGX-314, which is currently in phase 2 clinical trials.
Let's t... | Earlier this month, AbbVie (NYSE: ABBV) announced a deal with biotechnology company Regenxbio (NASDAQ: RGNX) to treat eye disorders using gene therapy. Assuming that the wet AMD and diabetic retinopathy markets continue their current growth rates, this would work out to $2.1 billion in annual sales for AbbVie by 2030 (... | For a company that analysts expect will generate $56.3 billion in revenue this year, $1 billion-plus in additional annual sales is enough to move the needle for AbbVie. Earlier this month, AbbVie (NYSE: ABBV) announced a deal with biotechnology company Regenxbio (NASDAQ: RGNX) to treat eye disorders using gene therapy.... | In the agreement AbbVie will pay $370 million up front to Regenxbio, while the latter could also receive up to $1.38 billion from AbbVie based on developmental and commercial milestones. Assuming that the wet AMD and diabetic retinopathy markets continue their current growth rates, this would work out to $2.1 billion i... | Earlier this month, AbbVie (NYSE: ABBV) announced a deal with biotechnology company Regenxbio (NASDAQ: RGNX) to treat eye disorders using gene therapy. Let's take a deeper look at this agreement, and the potential revenue it could generate for AbbVie. In the agreement AbbVie will pay $370 million up front to Regenxbio,... |
23,896 | 2021-09-27 00:00:00 UTC | 3 High-Yield Dividend Stocks Warren Buffett Loves | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-warren-buffett-loves-2021-09-27 | null | null | Few CEOs have delivered the green to their shareholders quite like billionaire Warren Buffett. Since taking the helm of conglomerate Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, he's led his company to an average annual return of 20%. That might not sound all too nominally impressive, but he's overseen the cr... | AbbVie: 4.8% yield Warren Buffett and his team also seem to love pharmaceutical stock AbbVie (NYSE: ABBV), which is parsing out a nearly 5% yield. It's no secret that anti-inflammatory drug Humira is what makes AbbVie tick. Humira's multiple indications and its global reach effectively ensure that it'll remain a cash c... | AbbVie: 4.8% yield Warren Buffett and his team also seem to love pharmaceutical stock AbbVie (NYSE: ABBV), which is parsing out a nearly 5% yield. It's no secret that anti-inflammatory drug Humira is what makes AbbVie tick. Humira's multiple indications and its global reach effectively ensure that it'll remain a cash c... | AbbVie: 4.8% yield Warren Buffett and his team also seem to love pharmaceutical stock AbbVie (NYSE: ABBV), which is parsing out a nearly 5% yield. It's no secret that anti-inflammatory drug Humira is what makes AbbVie tick. Humira's multiple indications and its global reach effectively ensure that it'll remain a cash c... | AbbVie: 4.8% yield Warren Buffett and his team also seem to love pharmaceutical stock AbbVie (NYSE: ABBV), which is parsing out a nearly 5% yield. It's no secret that anti-inflammatory drug Humira is what makes AbbVie tick. Humira's multiple indications and its global reach effectively ensure that it'll remain a cash c... |
23,897 | 2021-09-27 00:00:00 UTC | Pfizer begins study for COVID-19 antiviral drug | ABBV | https://www.nasdaq.com/articles/pfizer-begins-study-for-covid-19-antiviral-drug-2021-09-27 | null | null | Sept 27 (Reuters) - Pfizer Inc PFE.N said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri)
((manojn... | Sept 27 (Reuters) - Pfizer Inc PFE.N said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri) ((manojn... | Sept 27 (Reuters) - Pfizer Inc PFE.N said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri) ((manojn... | Sept 27 (Reuters) - Pfizer Inc PFE.N said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri) ((manojn... | Sept 27 (Reuters) - Pfizer Inc PFE.N said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug, to be co-administered with HIV drug ritonavir, for the prevention of COVID-19 infection. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Krishna Chandra Eluri) ((manojn... |
23,898 | 2021-09-25 00:00:00 UTC | Why AbbVie Just Made a $1.8 Billion Gene Therapy Deal | ABBV | https://www.nasdaq.com/articles/why-abbvie-just-made-a-%241.8-billion-gene-therapy-deal-2021-09-25 | null | null | AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. The deal could be worth up to nearly $1.8 billion including milestone payments. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Kei... | AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. I think it's a fairly good risk, but I think it's a better deal for Regenxbio and it's probably has something to do with AbbVie's need for near-term catalysts an... | AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio. 10... | AbbVie (NYSE: ABBV) recently announced a collaboration with Regenxbio (NASDAQ: RGNX) to develop a gene therapy targeting wet age-related macular degeneration. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss why AbbVie is teaming up with Regenxbio. I ... | AbbVie, the ticker for AbbVie as ABBV. I think it's a fairly good risk, but I think it's a better deal for Regenxbio and it's probably has something to do with AbbVie's need for near-term catalysts and the lack of Phase III products on the market by small companies that they want to find a partner. AbbVie (NYSE: ABBV) ... |
23,899 | 2021-09-23 00:00:00 UTC | Linda Evangelista files $50 mln lawsuit over disfiguring cosmetic treatment | ABBV | https://www.nasdaq.com/articles/linda-evangelista-files-%2450-mln-lawsuit-over-disfiguring-cosmetic-treatment-2021-09-23 | null | null | LOS ANGELES, Sept 23 (Reuters) - Former supermodel Linda Evangelista has filed a $50 million lawsuit over cosmetic procedures that she says left her "brutally disfigured" and turned her into a recluse.
The Canadian model, one of the biggest figures on runways and magazine covers in the 1990s, said in an Instagram post ... | Zeltiq Aesthetics, a unit of Allergan Aesthetics and parent company AbbVie ABBV.N, did not return a call for comment. LOS ANGELES, Sept 23 (Reuters) - Former supermodel Linda Evangelista has filed a $50 million lawsuit over cosmetic procedures that she says left her "brutally disfigured" and turned her into a recluse. ... | Zeltiq Aesthetics, a unit of Allergan Aesthetics and parent company AbbVie ABBV.N, did not return a call for comment. LOS ANGELES, Sept 23 (Reuters) - Former supermodel Linda Evangelista has filed a $50 million lawsuit over cosmetic procedures that she says left her "brutally disfigured" and turned her into a recluse. ... | Zeltiq Aesthetics, a unit of Allergan Aesthetics and parent company AbbVie ABBV.N, did not return a call for comment. LOS ANGELES, Sept 23 (Reuters) - Former supermodel Linda Evangelista has filed a $50 million lawsuit over cosmetic procedures that she says left her "brutally disfigured" and turned her into a recluse. ... | Zeltiq Aesthetics, a unit of Allergan Aesthetics and parent company AbbVie ABBV.N, did not return a call for comment. LOS ANGELES, Sept 23 (Reuters) - Former supermodel Linda Evangelista has filed a $50 million lawsuit over cosmetic procedures that she says left her "brutally disfigured" and turned her into a recluse. ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.